The role of the monomeric GTPase RhoA in cardiac fibroblasts by Jatho, Aline
 
 
The role of the monomeric GTPase RhoA 




for the award of the degree 
"Doctor rerum naturalium" (Dr.rer.nat.) 
(alternatively: "Doctor of Philosophy" Ph.D. Division of Mathematics and Natural 
Sciences) 
of the Georg-August-Universität Göttingen 
 
 
within the doctoral program Chemistry 
of the Georg-August University School of Science (GAUSS) 
 
 
submitted by Aline Jatho 
from Göttingen  
Göttingen, 2014 
 
Prof. Claudia Steinem, Institute of Organic and Biomolecular Chemistry, Göttingen 
Thesis Committee: 
Prof. Walter Stühmer, Max-Planck-Institute for Experimental Medicine, Göttingen 
 
 
Members of the examination board: 
Prof. Claudia Steinem, Institute of Organic and Biomolecular Chemistry, Göttingen 
Prof. Walter Stühmer, Max-Planck-Institute for Experimental Medicine, Göttingen 
 
Prof. Susanne Lutz, Institute of Pharmacology, Göttingen 
 
Further members of the examination board: 
Prof. Dörthe Katschinski, Department of Cardiovascular Physiology, Göttingen 
PD Kaomei Guan-Schmidt, Department of Cardiology and Pneumology, Göttingen  
Prof. Jörg Großhans, Institute of Biochemistry and Molecular Cell Biology, Göttingen 
 
 













































The last four years were an exciting and educational journey for me. I learned so much 
about the basic science of cardiovascular diseases, myself and from others that it is not a 
hard job at all to fill the “Acknowledgements” paragraph. 
I would like to thank my thesis committee Prof. Claudia Steinem and Prof. Walter Stühmer 
for participating and the interesting questions and discussions during my progress report 
presentations.  
Many thanks go also to the other members of the examination board to agree on this 
position and participating in my oral examination. 
Thank you, Prof. Zimmermann, for giving me the opportunity to work on my thesis in the 
institute of pharmacology, to be a member of the heart center and to become a young 
scientist of the DZHK. 
But of course I am most grateful for the support and the supervision of my group leader 
Susanne Lutz. I moved to pharmacology from a whole different area of research and had a 
long way to go when I started in the institute four years ago. You helped me from the start 
with every small question, taught me methods, proper presentations, scientific writing, not 
believing everything I see and how I can still improve my performance in all these aspects. 
You encouraged me to present my data on congresses and supported me every day with 
advice, reasonable doubt and new ideas for this exciting project you assigned me to.  
I would like also to thank my workgroup, the old and new members: Anita, Christina, Kerstin, 
Naim, Sebastian and Svenja for chat, advice and punctual lunch breaks. In particular I want 
to thank Beate to jump in, when I ran out of time, for strong coffee when it was needed and 
the constant reminder of positive thinking.  
Finally, I would like to thank the whole institute of pharmacology. It was a great time and I 
will miss you all. 
Ahmad, thank you for supporting me all this time with a helping hand, with sympathy and 
just for always being there for me. 
 
<I Table of Contents 
I 
I Table of Contents 
I Table of Contents ................................................................................................................. I 
II List of Abbreviations ........................................................................................................... V 
III List of Figures .................................................................................................................... X 
IV List of Tables ................................................................................................................... XII 
1  Summary ........................................................................................................................ 1 
1.1. Zusammenfassung ..................................................................................................... 1 
2  Introduction .................................................................................................................... 3 
2.1 Monomeric GTPases ............................................................................................... 3 
2.2 Rho GTPases .......................................................................................................... 3 
2.2.1 Structure of Rho GTPases ............................................................................... 3 
2.2.2 Mechanism of Rho GTPase activation ............................................................. 5 
2.2.3 Functions of Rho GTPases .............................................................................. 7 
2.3 RhoA-The Ras homolog family member A .............................................................. 7 
2.4 Activation of RhoA ................................................................................................... 8 
2.5 Downstream effects of RhoA signaling ...................................................................10 
2.5.1 Effect of RhoA on the actin cytoskeleton .........................................................10 
2.5.2 Effects of RhoA on microtubule structure ........................................................12 
2.5.3 Effects of RhoA on gene transcription .............................................................13 
2.5.4 Effects of RhoA on secretion ...........................................................................13 
2.5.5 Effect of RhoA in proliferation ..........................................................................14 
2.6 Pathological cardiac remodeling .............................................................................15 
2.7 The cardiac fibroblast .............................................................................................16 
2.8 The activated fibroblasts - myofibroblasts ...............................................................17 
2.9 RhoA and its effectors in the heart .........................................................................19 
3  Aim of the thesis ............................................................................................................22 
4  Material and Methods ....................................................................................................23 
4.1 Material ..................................................................................................................23 
4.1.1 Devices and plastic material ...............................................................................23 
4.1.2 Chemicals and media .........................................................................................25 
4.1.3 Media ..................................................................................................................28 
4.1.4 Buffers ................................................................................................................31 
4.1.5 Antibodies ...........................................................................................................34 
4.1.6 Enzymes and Kits ...............................................................................................36 
4.1.7 Primer .................................................................................................................37 
4.1.8 Plasmids .............................................................................................................38 
<I Table of Contents 
II 
4.1.9 Viruses ...............................................................................................................38 
4.1.10 Cells and bacteria ...............................................................................................39 
4.1.11 Software .............................................................................................................40 
4.2 Methods .................................................................................................................41 
4.2.1 Cell biological methods .......................................................................................41 
4.2.1.1 Neonatal rat cardiac fibroblast isolation .............................................................41 
4.2.1.2 Cardiac fibroblast/cardiomyocyte separation .....................................................41 
4.2.1.3 Cell cultivation and passaging ...........................................................................41 
4.2.1.4 Lentivirus production .........................................................................................42 
4.2.1.5 Lentivirus purification .........................................................................................43 
4.2.1.6 Lentiviral infection of NRCF ...............................................................................43 
4.2.1.7 Amplification of Adenoviruses ............................................................................43 
4.2.1.8 Casting of engineered heart muscle (EHM) .......................................................44 
4.2.1.9 Contraction measurements of engineered heart muscle ....................................45 
4.2.1.10 Protein isolation from EHMs ............................................................................45 
4.2.1.11 Annexin-V-FLUOS/propidium iodide staining ...................................................45 
4.2.1.12 Phalloidin staining of the actin cytoskeleton .....................................................46 
4.2.1.13 Immunofluorescence .......................................................................................46 
4.2.1.14 Evaluation of Golgi size and density by ImageJ ...............................................46 
4.2.1.15 Adhesion assay ...............................................................................................47 
4.2.1.16 2D-Migration assay ..........................................................................................47 
4.2.1.17 Amoeboid migration assay...............................................................................47 
4.2.1.18 Proliferation-DAPI-assay .................................................................................48 
4.2.1.19 Rho activity binding assay-pulldown assay ......................................................48 
4.2.2 Molecular biological methods ..............................................................................48 
4.2.2.1 Quantitative real time PCR (qRT-PCR) ..............................................................48 
4.2.2.2. End point polymerase chain reaction (PCR) .....................................................50 
4.2.2.3. Cloning strategy ................................................................................................51 
4.2.2.4 Restriction Digest ..............................................................................................51 
4.2.2.5 Ligation ..............................................................................................................51 
4.2.2.6 Transformation ..................................................................................................52 
4.2.2.7 DNA isolation .....................................................................................................52 
4.2.3 Protein chemical methods ...................................................................................52 
4.2.3.1. Preparation of protein samples for SDS-PAGE .................................................52 
4.2.3.2. Bradford assay .................................................................................................52 
4.2.3.3. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) ........53 
<I Table of Contents 
III 
4.2.3.4. Immunoblot .......................................................................................................53 
4.3. Statistics ....................................................................................................................54 
5 Results ..........................................................................................................................55 
5.1 Influence of RhoA on the morphology of NRCF and on the Golgi apparatus ..........55 
5.1.1 The lentiviral-induced knockdown is RhoA-specific .........................................55 
5.1.2 RhoA knockdown disrupts the cytoskeleton and changes cell morphology ......57 
5.1.3 Reduction of RhoA influences cytoskeletal protein expression ........................58 
5.1.4 Actin structures of higher order are reduced in RhoA knockdown cells ...........60 
5.1.5 Localization of cytoskeletal proteins is not altered in lentiviral-infected NRCF .61 
5.1.6 The Golgi apparatus morphology is changed in lentiviral-infected NRCF ........64 
5.1.7 Tubastatin A rescues the Golgi apparatus in RhoA knockdown cells ...............65 
5.1.8 Latrunculin A disrupts f-actin but does not change cytoskeletal protein 
expression in wild type NRCF ........................................................................................66 
5.1.9 Inhibition of ROCK affects the cell morphology but not the Golgi structure or 
cytoskeletal protein expression in wild type NRCF ........................................................67 
5.2 Influence of RhoA on the morphology of focal adhesion sites and on the adhesion 
velocity of NRCF ...............................................................................................................69 
5.2.1 The RhoA knockdown leads to a random distribution and reduced length of 
focal adhesion sites .......................................................................................................69 
5.2.2 The knockdown of RhoA increases the adhesion velocity ...............................70 
5.3 Influence of RhoA on the migration capacity of NRCF ............................................71 
5.3.1 The knockdown of RhoA impairs the migration performance on a plane surface 
  ........................................................................................................................71 
5.3.2 The invasive migration capacity is improved after RhoA knockdown but not 
after inhibitor treatment..................................................................................................72 
5.4 Influence of RhoA on the proliferation of NRCF ......................................................73 
5.4.1 The knockdown of RhoA increases the doubling time of NRCF as does HDAC6 
inhibition 74 
5.4.2 ROCK and HDAC6 inhibitors affect the actin cytoskeleton and the proliferation 
of normal adult human ventricular cardiac fibroblasts ....................................................75 
5.5 Influence of RhoA on the regulation of CTGF in NRCF ..........................................76 
5.5.1 CTGF co-localizes with the Golgi apparatus and acetylated tubulin ................77 
5.5.2 The knockdown of RhoA affects the expression and secretion of CTGF under 
low-serum conditions in NRCF ......................................................................................77 
5.5.3 Hyperacetylated tubulin increases extracellular CTGF solely in RhoA 
knockdown NRCF .........................................................................................................79 
5.6 Influence of RhoA on the contractile performance of engineered heart muscles .....80 
5.6.1 shRhoA NRCF complemented EHM develop less contractile force .................80 
<I Table of Contents 
IV 
5.6.2 EHM complemented with RhoA knockdown cells express less α-sm-actin and 
calsequestrin .................................................................................................................81 
5.7 Outlook ...................................................................................................................82 
6. Discussion .....................................................................................................................84 
6.1 RhoA influences the cytoskeleton, the cell morphology and the adhesion of NRCF .. 
  ...............................................................................................................................84 
6.2 RhoA influences NRCF migration ...........................................................................86 
6.3 RhoA controls myofibroblast proliferation by changes in tubulin stability ................86 
6.6 RhoA controls intracellular and extracellular CTGF and a change in Golgi 
morphology in NRCF ........................................................................................................87 
6.7 EHM complemented with shRhoA NRCF develop less contractile force and show 
signs of cardiomyocyte loss ..............................................................................................88 
6.8 Conclusion .............................................................................................................89 
7.  Literature .......................................................................................................................90 
 
II List of Abbreviations 
V 




ADP Adenosine triphosphate 
Ang II Angiotensin II 
ANF Atrial natriuretic factor 
ANP Atrial natriuretic protein 
APS Ammonium persulfate 
AT1R Angiotensin II-type 1 receptor 
BDM 2,3-Butanedione monoxime 
β-MHC β-Myosin heavy chain 
BNP Brain natriuretic protein 
BSA Bovine serum albumin 
C Cytosine 
C3T Clostridium botulinum C3 transferase 
CBFHH Calcium and bicarbonate-free Hanks’ 
solution with HEPES  
CEE Chicken embryo extract 
CO2 Carbon dioxide 




DMEM Dulbecco´s modified eagle medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
dNTP Deoxyribonucleoside triphosphate 
ECM Extracellular matrix 
EDTA Ethylenediaminetetraacetic acid 
EGF Epidermal growth factor 
II List of Abbreviations 
VI 
EGFP Enhanced green fluorescent protein 
EHM Engineered heart muscle 
EMT Epithelial-mesenchymal transition 
ET-1 Endothelin-1 
ET-R Endothelin-1 receptor 
FAK Focal adhesion kinase 
FCS Fetal calf serum 
FITC Fluorescein isothiocyanate 
G Guanine 
G1 phase Gap 1 phase 
G2 phase Gap 2 phase 
GAP GTPase-activating protein 
GDI Guanine nucleotide dissociation inhibitor 
GDP Guanosine diphosphate 
GEF Guanine nucleotide exchange factor 
GFP Green fluorescent protein 
GOI Gene of interest 
GPCR G-protein-coupled receptors 
GTP Guanosine triphosphate 
GTPγS Guanosine 5'-O-[gamma-thio]triphosphate 
H2O Water 




HCl Hydrogen chloride 
HDAC6 Histone deacetylase 6 
HEK293A Human embryonic kidney 293A cells 
HEPES 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid 
HIV-1 Human immunodeficiency virus type 1 
HUVEC Human umbilical vein endothelial cells 




LARG Leukemia-associated RhoGEF 
LatA Latrunculin A 
LB Lysogeny broth 
M1R Muscarinic M1 acetylcholine receptor 
MAL Megakaryocytic acute leukemia 
MEF Mouse embryonic fibroblast 
MI Myocardial infarction 
MMP Matrix metalloproteinases 
NADP(H) Nicotinamide adenine dinucleotide 
phosphate 
NaOH Sodium hydroxide 
NEAA Non-essential amino acids 
NHCF Normal human cardiac fibroblast 
NKM Non-cardiomyocyte medium 
NRCF Neonatal rat cardiac fibroblast 
NRCM Neonatal rat cardiomyocyte 
PBGD Porphobilinogen deaminase 
PBS Phosphate-buffered saline 
PCR Polymerase chain reaction 
PE Phenylephrine 
PenStrep Penicillin/streptomycin 
qRT-PCR Quantitative real time polymerase chain 
reaction 
RBD Rho binding domain of rhotekin 
RhoA Ras homolog (gene) family member A 
RNA Ribonucleic acid 
ROCK Rho-associated kinase 
S phase Synthesis phase 
S1PR Sphingosine-1-phosphate receptor 
SAM S-adenosyl methionine 
II List of Abbreviations 
VIII 
SDS Sodium dodecyl sulfate 
SEM Standard error of the mean 
SRF Serum response factor 
T Thymine 
TBS Tris-buffered saline 
TBST Tris-buffered saline with Tween 20 
TEMED Tetramethylethylendiamine 
TGF-β Transforming growth factor-β 
TNF-α Tumor necrosis factor-α 
TPPP1 Tubulin polymerization promoting protein 1 
Tris Tris(hydroxymethyl)aminomethane 
TRITC Tetramethylrhodamine 
TubA Tubastatin A 
 









k Kilo (103) 
kb Kilo basepairs 
L Liter 
µ Micro (10-6) 
m Milli (10-3) 
min Minute 
M Molar concentration 
II List of Abbreviations 
IX 




III List of Figures 
X 
III List of Figures  
Figure 2.1: Rho GTPases phylogenetic tree, homologies and mouse models ...................... 4 
Figure 2.2: Amino acid sequence comparison of human Rho GTPases ............................... 5 
Figure 2.3: Activation cycle of GTPases ............................................................................... 6 
Figure 2.4: Crystal structure of RhoA-GTPγS ........................................................................ 8 
Figure 2.5: Effect of RhoA overexpression on the actin cytoskeleton ...................................10 
Figure 2.6: Different cases of remodeling in cardiac myopathies .........................................16 
Figure 2.7: Sources of myofibroblasts .................................................................................18 
Figure 2.8: Role of Rho-associated kinases (ROCKs) in cardiovascular diseases ...............20 
Figure 3.1: Cloning strategy.................................................................................................51 
Figure 5.1: Analyses of RhoA, RhoB and RhoC expression in shControl and shRhoA NRCF
 .............................................................................................................................................55 
Figure 5.2: Angiotensin II-dependent RhoA activation in shRhoA and shControl NRCF ......56 
Figure 5.3: Evaluation of changes in cell morphology and volume of shControl and shRhoA 
NRCF ...................................................................................................................................57 
Figure 5.4: Immunoblot analyses of changes in cytoskeletal protein expression and 
modification ..........................................................................................................................58 
Figure 5.5: Evaluation of HDAC6 expression on in shRhoA and shControl NRCF ...............59 
Figure 5.6: Analysis of protein acetylation in the particulate and soluble fractions of shRhoA 
and shControl NRCF ............................................................................................................60 
Figure 5.7: Evaluation of geodesic dome structures in shRhoA and shControl NRCF .........61 
Figure 5.8: Immunostaining of β- and γ-actin isoforms in shRhoA and shControl NRCF ......62 
Figure 5.9: Immunostaining of α-sm-actin in shRhoA and shControl NRCF .........................62 
Figure 5.10: Immunostaining of vimentin and α-tubulin in shRhoA and shControl NRCF .....63 
Figure 5.11: Co-staining of acetylated tubulin and the Golgi apparatus in shRhoA and 
shControl NRCF ...................................................................................................................64 
Figure 5.12: Evaluation of the Golgi apparatus size and density in shRhoA and shControl 
NRCF ...................................................................................................................................65 
Figure 5.13: Analysis of the Golgi apparatus structure in shRhoA and shControl NRCF 
treated with TubA .................................................................................................................65 
Figure 5.14: Impact of LatA on the cytoskeleton and the Golgi apparatus in NRCF .............66 
Figure 5.15: Morphometric analysis of fasudil-, H1152P- and TubA-treated wild type NRCF
 .............................................................................................................................................68 
Figure 5.16: Morphometric analysis of the Golgi apparatus of wild type NRCF after fasudil 
and TubA treatment ..............................................................................................................68 
Figure 5.17: Analysis of protein expression in fasudil- and TubA-treated wild type NRCF ...69 
III List of Figures 
XI 
Figure 5.18: Analysis of focal adhesion site size and distribution .........................................70 
Figure 5.19: Analysis of the adhesion velocity of shRhoA and shControl NRCF ..................71 
Figure 5.20: Analysis of the migration ..................................................................................72 
Figure 5.21: Analysis of the invasive migration ....................................................................73 
Figure 5.22: Analysis of proliferation and cell death of sRhoA and shControl NRCF ...........74 
Figure 5.23: Analysis of the proliferation of NRCF treated with ROCK inhibitors and TubA .75 
Figure 5.24: Analysis of the actin cytoskeleton and the proliferation after treatment with 
ROCK inhibitiors and TubA in ...............................................................................................76 
Figure 5.25: Co-stainings of acetylated tubulin, the Golgi apparatus and CTGF in shControl 
and shRhoA NRCF ...............................................................................................................77 
Figure 5.26: Analysis of CTGF expression and secretion in shRhoA and shControl NRCF 
under serum-reduced conditions ..........................................................................................78 
Figure 5.27: Analysis of CTGF expression and secretion in shRhoA and shControl NRCF 
under high serum conditions.................................................................................................78 
Figure 5.28: Analysis of CTGF expression and secretion in shRhoA and shControl NRCF 
under high serum conditions and additional TubA treatment ................................................79 
Figure 5.29: Contraction experiments of EHM complemented with shControl and shRhoA 
NRCF ...................................................................................................................................80 
Figure 5.30: Analysis of protein composition of EHM complemented with shControl and 
shRhoA NRCF......................................................................................................................81 
Figure 5.31: Analysis of the BiFC sensor protein expression in HEK293A cells by 
immunoblot ...........................................................................................................................82 
Figure 5.32: Analysis of the BiFC sensor expression in HEK293A cells by fluorescence 
microscopy ...........................................................................................................................83 
IV List of Tables 
XII 
IV List of Tables 
Table 4.1: Devices ...............................................................................................................24 
Table 4.2: Plastic material ....................................................................................................25 
Table 4.3: Chemicals and media ..........................................................................................27 
Table 4.4: Primary antibodies ..............................................................................................35 
Table 4.5: Secondary antibodies for immunoblot analyses ..................................................35 
Table 4.6: Secondary antibodies for immunofluorescence analyses ....................................35 
Table 4.7: Fluorophore-conjugated phallotoxin and wheat germ agglutinin ..........................36 
Table 4.8: Kits ......................................................................................................................36 
Table 4.9: PCR enzymes .....................................................................................................36 
Table 4.10: Restriction enzymes ..........................................................................................37 
Table 4.11: Primer ...............................................................................................................37 
Table 4.12: Plasmids ...........................................................................................................38 
Table 4.13: Lentivirus plasmids ............................................................................................39 
Table 4.14: Cells ..................................................................................................................39 
Table 4.15: Software ............................................................................................................40 
Table 4.16: Transfection mixture for 10 cm culture dish .......................................................42 
Table 4.17: Master mix for 4 EHMs ......................................................................................44 
Table 4.18: qRT-PCR mixture ..............................................................................................49 
Table 4.19: qRT-PCR protocol .............................................................................................49 
Table 4.20: PCR mixture ......................................................................................................50 
Table 4.21: PCR protocol .....................................................................................................50 
 
1  Summary 
1 
1  Summary 
 
The specific knockdown of RhoA in neonatal cardiac fibroblasts led on a molecular level to a 
decreased expression of the myofibroblast marker α-smooth muscle actin and an increase in 
the modified acetylated tubulin. On the subcellular level a loss of stress fibers and actin 
structures of higher order as well as a more compact Golgi apparatus were found. In 
addition, focal adhesion sites were smaller and randomly distributed implicating a loss in cell 
polarity. On a cellular level, the knockdown of RhoA led to an increase in cell area but not in 
cell volume. The functional outcomes of these changes were a faster adhesion independent 
of the substrate, a reduction in the migration capacity on a focal plane and, in contrast, an 
increase in the invasive migration through pores. Moreover, the mitogenic response to serum 
was strongly reduced without a change in cell viability. The expression and secretion of the 
fibrosis-associated CTGF in starved cells was significantly reduced by a lower expression of 
RhoA, which was however circumvented in the presence of serum. On a heterogeneous 
multicellular level, the knockdown of RhoA in NRCF impaired the contractile function of 
engineered cardiac tissue under calcium stimulation which was accompanied by a decreased 
expression of α-smooth muscle actin and calsequestrin. By using specific inhibitors for the 
RhoA-dependent kinases (ROCK) and HDAC6 several of these changes could be imitated 
and thus these downstream effectors assigned to certain functions. By using the ROCK 
inhibitor fasudil the morphological changes and the impaired migration capacity could be 
mimicked in wild type fibroblasts whereas the decrease in cell proliferation was detected after 




Der spezifische Knockdown von RhoA in neonatalen kardialen Rattenfibroblasten führte auf 
molekularem Level zu einer Reduktion des Myofibroblastenmarkers α-Glattmuskelaktin und 
zu einem Anstieg im modifizierten acetylierten Tubulin. Auf subzellulärer Ebene konnte ein 
Verlust von Stressfasern, Aktinstrukturen höherer Ordnung und eine erhöhte Dichte des 
Golgi-Apparats beobachtet werden. Außerdem waren die Fokaladhäsionen kürzer und 
zufällig verteilt, was auf einen Verlust der Zellpolarität hinweist. Auf dem zellulären Level 
erhöhte der Knockdown von RhoA die Zellfläche aber nicht das Volumen. Diese 
Veränderungen führten zu einer schnelleren Adhäsion unabhängig vom Substrat, eine 
Reduktion der Migration in 2D und im Gegensatz dazu eine verbesserte Migration durch eine 
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poröse Membran. Außerdem war die mitogene Antwort der Zellen auf einen Serumstimulus 
stark reduziert. Eine Veränderung in Zellviabilität konnte zudem nicht beobachtet werden. 
Die Expression und Sekretion des Fibrose-assoziierten Faktors CTGF war in gehungerten 
Zellen mit einer Reduktion in RhoA Expression signifikant vermindert, was jedoch in der 
Anwesenheit eines Serumstimulus aufgehoben werden konnte. Auf einer heterogenen 
multizellulären Ebene verringerte der Knockdown von RhoA die kontraktile Funktion von 
generierten künstlichen Herzgeweben unter Kalziumstimulation. Dies ging einher mit einer 
Reduktion der Expression von α-Glattmuskelaktin und Calsequestrin. Durch die Verwendung 
spezifischer Inhibitoren der Rho-assoziierten Kinase (ROCK) und HDAC6 konnten einige 
dieser zellulären Veränderungen imitiert und demensprechend einem Effektorprotein 
zugeordnet werden. Der ROCK Inhibitor Fasudil konnte die morphologischen Veränderungen 
und die reduzierte Migrationskapazität in Wildtyp-Fibroblasten abbilden, wobei eine 
Reduktion der Proliferation nach der Verwendung des HDAC6 Inhibitors Tubastatin A 
beobachtet wurde. 
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2  Introduction 
 
2.1 Monomeric GTPases 
 
The low molecular weight superfamily of monomeric guanosine triphosphatases (GTPases) 
ranging in size between 20 and 40 kDa consists of more than 150 known members in 
humans. All members share their function as binary molecular switches and as such they 
bind and hydrolyse guanosine triphosphate (GTP) with the help of accessory proteins similar 
to the α-subunits of heterotrimeric G-proteins.  
Based on structural and functional similarities monomeric GTPases can be divided into five 
subfamilies which are Ras, Arf/Sar1, Rab, Ran and Rho. [1, 2] In the last decades distinct 
members of these five subgroups were identified showing involvement in a wide spectrum of 
cellular processes. Most of these proteins are still under investigation, some still poorly 
understood. The Ras family proteins are currently intensively investigated targets because of 
their role in human oncogenesis in that regard functioning as signaling nodes transferring 
extracellular stimuli to multiple downstream effectors and influencing cell differentiation, 
survival and proliferation [1]. Arf1, the name giving and best characterized protein of this 
subfamily was found to be involved in vesicle coating processes and transport whereas 
another group member, Arf6, was identifies as a regulator of actin structures in cell 
membrane ruffles [3]. A very similar function was found for the members of the Rab 
GTPases, which represent the largest subgroup. These proteins were found to be involved in 
vesicle formation, actin- and tubulin-dependent vesicle movement, and membrane fusion [4]. 
A completely different function was identified for Ran, who is known to be involved in nuclear 
transport processes mediated by importins as well as in cell cycle regulation [5]. The latter is 
also true for some of the Rho GTPases which were furthermore found to be strong regulators 
of the actin cytoskeleton [6]. 
 
2.2 Rho GTPases 
 
2.2.1 Structure of Rho GTPases 
 
To date, the subfamily of Rho GTPases consists of 20 members in humans with many of 
them ubiquitously expressed. Evolutionary research of the branches´ origin revealed that the 
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monomeric GTPase Rac is the founder and the oldest known protein of this structure found 
in mycetozoans evolving over one billion years ago [7]. Rho family members share up to 
95% homology within their own subgroup [6] and display 30% identity with other members of 
the Ras superfamily. However, classical proteins of the Rho family (see Figure 2.1, blue) can 
be distinguished from other monomeric GTPases by their specific Rho insert domain [8] 
located between the fifth β-strand and the fourth a-helix. 
 
Figure 2.1: Rho GTPases phylogenetic tree, homologies and mouse models Figure 
adapted from Heasman et al. 2008. Shown are the Rho family GTPases grouped based on 
sequence analysis with ClustalW. 
 
Within the Rho family distinct differences could be identified, e.g. classical members like 
RhoA, Rac1 and Cdc42 count 250 amino acids maximum while atypical members (Figure 
2.1, green) can count more than 700. Apart from that all Rho GTPases share a similar GTP-
binding site and two switch regions, which can differ in substitutions of single amino acids in 
different members (Figure 2.2.). In addition, most Rho GTPases are post-translationally 
modified at the C-terminus by an isoprenoid lipid which serves as an anchor to membranes 
of cell compartments after GTPase activation or as a binding moiety for guanine nucleotide 
dissociation inhibitors (RhoGDIs) [9-11]. The lipid residues vary with respect to the type of 
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different Rho GTPases, however, the most prominent motifs are geranylgeranyl- and 
farnesyl-residues covalently bound to the last cysteine in the proteins. 
 
 
Figure 2.2: Amino acid sequence comparison of human Rho GTPases Figure adapted 
from Ihara et al. 1998. The Figure shows the aligned sequences of RhoA-C including 
members of the Ras, Rac and Cdc42 family. Areas in yellow, red, green and blue are 
conserved regions, phosphate binding site and switch regions shown in black. 
 
2.2.2 Mechanism of Rho GTPase activation  
 
As mentioned above, all monomeric GTPases serve as binary molecular switches cycling 
between an inactive GDP- and an active GTP-bound state [13]. This nucleotide exchange is 
tightly regulated and involves a number of factors. Every GTPase can be activated by one or 
more of the 60 known guanine nucleotide exchange factors (RhoGEFs) which promote the 
slow intrinsic exchange activity of GDP with GTP [12, 13]. RhoGEFs bind to the GDP-bound 
GTPase and the protein complex formed promotes the dissociation of GDP from the GTPase 
leaving an empty binding pocket. As soon as this binding site is filled with a GTP molecule 
the GEF detaches from the GTPase. In many cases, the activated GTPase then translocate 
to the cell membrane where it interacts with downstream effectors [14].  
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Figure 2.3: Activation cycle of GTPases Figure adapted from Cherfils et al. 2013. Shown is 
the schematic activation by a guanine nucleotide exchange factor (GEF) with the 
translocation to the membrane and deactivation by a GTPase-activating protein (GAP) of 
GTP family proteins. 
To terminate the signaling event GTPase-activating proteins (RhoGAPs) bind to the activated 
monomeric GTPases and stimulate the intrinsic GTP hydrolytic activity. RhoGAPs lower the 
transition state energy of the hydrolysis reaction using an arginine-rich side chain to 
neutralize developing charges inside the catalytic pocket and activate water molecules inside 
to promote an in-line nucleophilic attack on the γ-phosphate of GTP [15, 16]. Upon hydrolysis 
of the GTP to GDP inside the catalytic pocket the protein is inactive again [17].  
With respect to signaling processes a number of RhoGEFs and RhoGAPs could be identified 
to be involved in specific cascades while others activate and deactivate a variety of GTPases 
and therefore causing an even wider spectrum of cellular responses [17]. 
To inhibit the proteins participation in signaling events the GTPases can be kept in an 
inactive state bound by RhoGDIs which cap their isoprenoid rest with a lipid binding pocket 
and therefore prevent the GTPases from binding to the cell membrane in their active state 
[18]. The signals for binding and releasing GTPases are believed to be protein typical 
phosphorylation patterns, however, these mechanisms are still under investigation [15]. 
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2.2.3 Functions of Rho GTPases 
 
Rho GTPases are known to be involved in a wide variety of cellular processes. RhoA, Rac1, 
Cdc42, TC10, TLC and Rnd1 were found to influence remodeling and turnover of the actin 
cytoskeleton, while RhoB, RhoC, Rac1b and Rac3 participate in tumor growth and 
metastasis [19]. Rac1 and Rac2 were identified to be part of NADPH complex and to induce 
the superoxide production in many cells [20, 21]. Other members of the Rho GTPase family, 
like RhoD or RhoH, are not well investigated. RhoD was solely shown to be involved in the 
transport of early endosomes as well as in the disruption of focal adhesion sites [6] and 
RhoH antagonizes the signaling of Rac1 [22]. 
Most of the functional information gathered around the Rho family and their impact on the 
cytoskeleton was obtained by studying RhoA, Rac1 and Cdc42. In various cell types it was 
shown that while RhoA regulates the assembly of contractile actin structures, Rac1 and 
Cdc42 control the polymerization of peripheral lamellipodial and filopodial protrusions, 
respectively [23]. Apart from this many other functions were associated with these GTPases 
including the regulation of gene transcription [24-26] 
 
2.3 RhoA-The Ras homolog family member A 
 
The ubiquitously expressed Ras homolog family member A (RhoA) is a member of the 
monomeric GTPase protein subfamily of Rho-related proteins and approximately 21 kDa in 
size [27]. Since its identification in 1985 [28], two more mammalian isoforms were 
discovered: RhoB [29] and RhoC [30]. They both share 83% homology with RhoA and were 
also found to be involved in tumor invasion and metastasis [31, 32]. Alike all monomeric 
GTPases, RhoA is functioning as a molecular switch, which is activated and deactivated by 
the exchange of GDP and GTP and GTP hydrolysis, respectively [12]. After activation the 
geranylgeranyl-residue bound to the C-terminus of the protein enables RhoA to translocate 
and attach to the cell membrane. Therefore, it can be isolated from both membrane and 
cytosolic fractions [33].  
2  Introduction 
8 
 
Figure 2.4: Crystal structure of RhoA-GTPγS adapted from Ihara et al. 1998. RhoA was 
found in a crystal structure along with the Mg2+ ion and three water molecules. 
RhoA shows a major structural feature, that is also persistent in Ras proteins and which 
consists of a six-stranded β-sheet (red) surrounded by five α-helices (blue) and two 310-
helices (green). When compared to Ras, a prominent structural difference in the crystal 
structure is the insert region which takes the form of a positively charged three turned helix 
and is specifically found in Rho-related GTPases. It is believed that this motif supports 
membrane binding of RhoA [34]. The ability of RhoA to exchange GDP to GTP is mediated 
by its two switch regions I and II, which undergo massive conformational changes upon 
guanine nucleotide binding. In addition, switch I was found to be involved into effector 
binding processes. Switch I was also shown to be exposed to the solvent and highly isolated 
within the Rho-related but not Ras-related proteins [35]. Moreover, both switch regions 
interact with the dbl-homology (DH) domain of GEFs, thereby contributing to the formation of 
the GTPase-RhoGEF complex and the GDP/GTP exchange [36]. 
 
2.4 Activation of RhoA 
 
RhoA was shown to be activated by diverse upstream signals. Amongst them many G-
protein-coupled receptors (GPCR) which can be activated by a wide spectrum of hormones 
and growth factors were identified like the sphingosine-1-phosphate receptor (S1PR) in 
cardiomyocytes [37], the angiotensin II-type 1 receptor (AT1R) in smooth muscle cells [7] and 
muscarinic M1 acetylcholine receptor (M1R) in embryonic neural crest cells [38].  
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GPCRs signal via heterotrimeric G proteins, which consist of an α- and β/γ-subunit. After 
receptor activation, the G proteins dissociate in the α-subunit and the β/γ-dimer each 
interacting with different downstream effectors which includes certain RhoGEFs. Especially, 
the subfamily of G12/13 proteins has been shown to activate RhoA and regulate via these 
pathways the cytoskeletal remodeling, proliferation, migration and invasion of cells [39, 40]. 
Mechanistically, Gα12/13-subunits activate RhoA by direct binding and stimulation of three 
distinct RhoGEFs: p115RhoGEF, PDZ-RhoGEF and the leukemia-associated RhoGEF 
(LARG) that were found to affect gastrulation, actin remodeling and gene expression via the 
serum response factor (SRF) [41-43]. In addition, G proteins of the Gq/11 subfamily on the 
other hand were found to be involved in smooth muscle contraction not only by increasing 
the intracellular calcium levels, but also by activating RhoA. Gαq/11-subunits activate RhoA 
through e.g. p63RhoGEF that was shown to mediate Ang II- and endothelin-1-dependent 
proliferation and contraction of rat aortic smooth muscle cells as well as the contractile 
properties of isolated vessels [17, 44].  
Another receptor family mediating RhoA signaling are receptor tyrosine kinases. These 
autophosphorylating transmembrane receptors have been shown to affect the actin 
cytoskeleton via RhoA activation in several cell types [45, 46]. For example, stimulation of 
the epidermal growth factor (EGF)-receptor has been shown to induce RhoA activation in 
cancer squamous cell carcinoma cells and thereby leading to the formation of stress fibers. 
This could be blocked by the inhibition of the Rho-effectors Rho-dependent kinases (ROCK) 
[47]. The EGF-receptor itself on the other hand can be activated independently from its 
ligands. By forming protein complexes with integrins, EGF-receptor signaling can also be 
induced by changes in extracellular matrix (ECM) composition or in focal adhesion turnover 
[48]. As a consequence this leads to a change in cofilin phosphorylation levels and therefore 
in actin polymerization dynamics [49]. EGF-receptor was found to influence RhoA activation 
in combination with β1-integrins via regulation of p190RhoGAP in a mouse epithelial gland 
cell line. Downstream signaling of the p190GAP pathway was observed to be involved in cell-
cell- and cell-matrix contacts involved in migration and metastasis [50]. Besides EGF-
receptor signaling RhoA can also directly be activated by changes in the ECM via integrins. 
These receptors connect the actin cytoskeleton to the extracellular scaffold and were 
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2.5 Downstream effects of RhoA signaling 
 
Inside the cell, RhoA has a wide variety of functions mostly connected to and mediated by 
the actin and tubulin cytoskeleton.  
 
2.5.1 Effect of RhoA on the actin cytoskeleton 
 
The actin cytoskeleton controls many processes in the cell like motility, secretion, 
proliferation and endocytosis. A tight spatial-temporal regulation of actin turnover is 
necessary to maintain these functions. In cells with a prominent cytoskeleton as for instance 
fibroblasts cell integrity is maintained by the cortical actin network and stress fibers [52, 53]. 
By microinjections of a constitutively active RhoA it was shown that RhoA can induce stress 
fibers in these cells, thereby identifying RhoA as a prominent regulator of the actin 
cytoskeleton [54]. Physiologically, this function plays a role in the regulation of cellular 
contraction of different cell types including smooth-muscle cells, but also of non-muscle cells 
[55]. Mechanistically, in smooth muscle cells RhoA activates ROCK which phosphorylates 
the myosin light chain phosphatase and thereby inhibits its activity. This consequently 
increases the phosphorylation of the myosin light chain which then results in the contraction 
of actin-myosin-containing fibers. At the same time the activation of ROCK activates LIM-
kinase which directly induces cofilin phosphorylation and therefore inhibits actin 
depolymerization and fiber disassembly [56].  
 
Figure 2.5: Effect of RhoA overexpression on the actin cytoskeleton Figure adapted 
from Hall et al. 1995. Shown is an actin staining of control Swiss 3T3 fibroblasts and cells 
overexpressing RhoA wild type protein. 
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Another pathway controlling the formation of actin fibers involves the formin mDia1 activation 
by RhoA. Formins can not only control polymerization speed, but also redirect g-actin to the 
plus-end of actin fibers and thus RhoA controls the formation of stress fibers and at the same 
time the actin turnover [57]. 
In addition, RhoA was found to be involved in the focal adhesion complex located at the 
stress fiber tip. These protein complexes, consisting of clusters of integrin receptors, vinculin, 
talin, paxilin as well as diverse signal mediators like RhoA which control the actin 
cytoskeleton dependent on the available extracellular substrate [58]. For example, in 
vascular smooth muscle cells it has been demonstrated that upon stress fiber formation 
induced by RhoA, the total number of focal adhesion sites increased, improving the cell 
contact to the substrate and the cytoskeletal contractility [59]. With respect to the heart 
muscle, the ECM is mostly composed of collagen I and III, laminin and fibronectin. Integrin 
receptors have been found to interact intensively with these matrix proteins. With a change in 
ECM elasticity, which is caused by a change in composition, RhoA was found to be activated 
by integrin receptor mediated signals [51].  
Controlling the remodeling of the actin cytoskeleton and the focal adhesion turnover makes 
RhoA also a strong regulator of migratory and invasive processes. Moreover, in various cell 
types it was found that RhoA contributes to the cell polarity and therefore to the direction of 
the movement by retracting the rear of the migrating cell [23]. Other studies report that RhoA 
can be found in the leading edge of migrating tumor cells. It was discovered that advanced 
carcinomas do not form thick stress fibers but thinner contractile filaments which can be 
observed after formin activation by RhoA with simultaneous ROCK pathway inhibition [60]. 
Later mDia2 was identified as the regulating factor activated by RhoA to mediate invasive 
migration in relevant 3D models [61].  
Furthermore, actin fibers are also necessary to break cell symmetry and polarize it for 
division. The contractile ring formed in the anaphase is induced by microtubule-mediated 
activation of the RhoA-ROCK pathway. The recruitment of actin and myosin fibers creates 
the ring at the cell cortex which separates the two daughter cells by contraction. In addition, it 
was found that inhibition of the actin polymerization hinders the effective separation of the 
centrosomes concluding that the remodeling and turnover of actin is necessary for this 
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2.5.2 Effects of RhoA on microtubule structure 
 
Very similar to actin fibers, microtubules are filaments shaped by constant turnover of subunit 
polymerization and depolymerization. Built-up by heterodimeric α- and β-tubulin forming a 
hollow tube with a pack of 13 strands, microtubules are a prominent structure-giving 
component of the cytoskeleton involved in cell division and vesicle trafficking [63]. 
Throughout the cell, different populations of microtubules can be found. Microtubules that 
differ in turnover speed are mostly found on the leading edge of a migrating cell [64]. Stable 
structures on the other hand are located in the perinuclear region where the microtubules 
organizing center is located [65]. α-tubulin, one of both monomers of microtubules, can be 
modified post-translationally by attachment and removal of i.e. tyrosine and acetyl residues. 
These modifications differ between stable and unstable populations of microtubules, which 
can be distinguished by their slow or fast depolymerization rate, respectively. However, role 
of these modifications in cellular processes is still under investigation [66]. For tubulin 
acetylation, which is the only modification occurring in the lumen of the microtubule, it has 
been shown that this modification stabilizes the microtubule [67]. 
Within single studies the impact of RhoA on microtubule turnover and stability mediated via 
the formin mDia1 was investigated [68, 69]. This pathway was found to be involved in 
microtubule reorganization, however, the details of this mechanism still remain obscure. 
Nevertheless, a subset of microtubules, which showed an increased loss of tyrosine residues 
(Glu-tubulin), were involved in cell migration and could be connected to RhoA activation by 
heterotrimeric G-proteins and GEFs [69]. Another study investigated the connection between 
focal adhesion sites and stable microtubules at the leading edge of migrating cells. It was 
hypothesized that integrin-mediated activation of the focal adhesion kinase (FAK) is able to 
activate the RhoA-mDia pathway, thereby increasing the fraction of local detyrosinated 
tubulin [70]. With regards to tubulin acetylation a RhoA-mDia2 mediated pathway was 
identified influencing the activity of the histone deacetylase 6 (HDAC6). HDAC6 is by 80% 
found in the cytosol and catalyses amongst others the deacetylation of tubulin and cortactin 
[71]. In osteoclasts it was observed that the overexpression of wild type RhoA or of the 
formin mDia2 activate the deacetylase activity of HDAC6 leading to a decrease in tubulin 
acetylation [72]. In addition it was found in bone osteosarcoma cells that the tubulin 
polymerization promoting protein 1 (TPPP1) can be phosphorylated by ROCK causing 
HDAC6 activation. Upon deacetylation of microtubules by the activated HDAC6, a faster 
microtubules turnover can be observed [73]. Nevertheless, the effect of RhoA on HDAC6 and 
acetylated tubulin in fibroblasts is poorly investigated. 
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2.5.3 Effects of RhoA on gene transcription 
 
In addition to its ability to modify the actin cytoskeleton, RhoA is also able to induce the 
transcription of cytoskeletal and ECM-associated genes like ACTA2 (α-smooth muscle actin) 
or COL1A2 (collagen I), respectively [74]. This occurs mainly indirectly through remodeling of 
actin fibers and changing the g/f-actin ratio which subsequently leads to the activation of the 
SRF [75]. This was supported by the finding that actin interfering drugs, which bind g-actin 
rather than promote actin polymerization, can activate SRF without Rho GTPase 
participation. Therefore, the level of free actin monomers is considered to create a feedback 
loop and in return activates regulatory mechanisms for the SRF [26]. This activation is 
mediated by the SRF co-activator megakaryocytic acute leukemia (MAL) which binds to g-
actin in the cytosol. Upon actin polymerization MAL dissociates from g-actin and translocates 
into the nucleus where it binds to and activates the SRF. Both, RhoA effectors mDia1 and 
ROCK were shown to indirectly mediate the dissociation of MAL from g-actin [76].  
 
2.5.4 Effects of RhoA on secretion  
 
The packaging of proteins into vesicular vehicles and their transport within the cell or to the 
plasma membrane is an important function in secreting cells. Secreted factors are 
transported away from the Golgi apparatus to be released into the intercellular space. [77]. 
The actin and tubulin cytoskeleton is known to be involved in vesicular transport processes, 
the fusion of membranes and exocytosis. Therefore, it is not surprising that RhoA is 
connected to the secretory behavior in various cell types [78]. 
First, it could be shown in mast cells that an inactivation of RhoA using the clostridium 
botulinum C3 transferase (C3T) which inhibits the GDP/GTP exchange in RhoA/B/C by ADP-
ribosylation impairs the secretion [79]. On the other hand, stimulation of the RhoA pathway in 
keloid fibroblasts by TGF-β increased the secretion of the connective tissue growth factor 
(CTGF) and collagen I [80]. In addition, vesicles coated with an f-actin structure were 
identified in alveolar type II cells that can release their content solely by actin contraction. In 
secretion assays no release of any surfactant from these actin-coated vesicles could be 
measured when the cells were treated with the actin monomer binding toxin latrunculin A 
(LatA). In this study, it was additionally shown that when active RhoA was inhibited by C3T 
no vesicle budding, vesicle actin coating or exocytosis occurred [81].The importance of the 
regulation of actin structures for the fusion of vesicles with the membrane and for 
stabilization of the vesicle-membrane connection were also shown in different other cell 
types [82]. Moreover, it was found in HeLa cells that the translocation of the exocyst complex 
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after its activation by GEF-H1 is mediated by RhoA. Inhibition of the exocyst complex 
translocation led to a reduction in exocytosis and therefore to an accumulation of vesicles 
inside the cells [83].  
In the heart muscle and in cardiac cells including cardiac fibroblasts, RhoA is implied to 
control the secretion of matrix metalloproteinases (MMP) which degrade the extracellular 
matrix (ECM) but also activate apoptotic ligands and influence cell-cell contacts [84]. Most 
studies discussing this topic show, that an inhibition of RhoA signaling using HMG-CoA-
reductase inhibitors (statins) affect RhoA activation and hence MMP secretion. This effect 
functions mainly via disabling the geranylgeranyl lipid residue synthesis [85]. The outcome of 
MMP secretion has been shown for example in a tumor cell model, here MMPs support the 
invasion into the tissue by degrading scaffold proteins and enhance the migration potential 
[86] In hepatocellular carcinoma models a reduction in tumor size, an increased tumor 
apoptosis rate and a decreased metastasis could be observed after the treatment of mice 
with the ROCK inhibitor Y-276323. Similar as describe for cardiac fibroblasts, RhoA could be 
linked to MMP secretion in this study. This led to the hypothesis that ROCK inhibition could 
be a possible target in anticancer therapy [87]. 
 
2.5.5 Effect of RhoA in proliferation 
 
The actin cytoskeleton and microtubule structures are equally involved and important in cell 
proliferation. While microtubules separate chromosomes during the anaphase, actin forms a 
part of the contractile ring that is essential for cytokinesis [88].  
In a number of publications the effect of RhoA, which has been shown to translocate to the 
cell cortex during ana-telophase in mitosis was investigated. In this context RhoA, which is 
activated by the RhoGEF ECT2 is mandatory for the formation of the contractile ring and 
thus for cytokinesis [89]. In addition, the stress fiber formation induced by RhoA was found to 
be involved in G1-S phase transition and mitotic cell rounding in Xenopus epithelial kidney 
cells [90]. The disruption of actin structures by LatA led in the same cell type from a different 
species to a G1 phase arrest and failure in centrosome separation. These effects were also 
induced by the inhibition of ROCK using Y27632 [91].  
 
During mitosis microtubules were found to stabilize an area at the furrow region. This area is 
then supporting the cortical ring where active RhoA is concentrated during cytokinesis. A 
pharmacological manipulation of microtubule structures led to a diffusion of active RhoA from 
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the already formed cortical ring or to a suppression of translocation to the forming cortical in 
star fish oocytes [92]. RhoA can also regulate the turnover of microtubules and therefore 
influence mitosis e.g. via ROCK and HDAC6. ROCK had been shown to phosphorylate 
TPPP1 which blocked its ability to inhibit HDAC6. This led to a rapid deacetylation of 
microtubules which enabled human osteosarcoma cells to progress through the cell cycle. In 
G2 phase TPPP1 was dephosphorylated and the resulting inhibition of HDAC6 allowed the 
stable mitotic apparatus to form [73]. 
With respect to the heart, just a few studies were published investigating the impact of RhoA 
on cell proliferation. It was found that in atrial fibroblasts RhoA influences the process of 
serum-driven proliferation. Upon treatment with simvastatin, which reduced the level of active 
RhoA at the membrane, the cells showed a decrease in proliferation rate by 50 to 70% [93]. 
Furthermore, for neonatal rat cardiac fibroblasts, it has been demonstrated that the induction 
of proliferation by Ang II or TGF-β could be almost completely blocked by the co-application 
of the ROCK inhibitor GSK-576371 [94].  
 
2.6 Pathological cardiac remodeling 
 
Heart remodeling can occur under physiological and pathological conditions. Physiological 
remodeling, which is in most cases a reversible process, develops during pregnancy or in the 
athletes´ heart and is characterized by a growth of cardiomyocytes in order to improve the 
contractile function and fulfill the body’s demand [95, 96]. In contrast, pathological 
remodeling which can be a consequence of genetic predisposition and diverse processes 
like persistent hypertension, valve malfunctions and infections causes mainly irreversible 
changes including cardiac hypertrophy, fibrosis and often later on cardiac dilation. As a 
consequence the contractile function of the heart is impaired and heart failure occurs [97, 
98]. 
During the progress of dysfunction, the heart muscle changes in shape, cellular composition 
and performance [99]. Initially, a thickening of the heart muscle by an increase in 
cardiomyocyte size is developed to compensate for the additional work load. Then, due to 
the high energy expenditure and the decreased perfusion of the heart cardiomyocytes 
undergo apoptosis [100] and the spaces are filled with extracellular matrix. Cardiac fibrosis 
occurs, which cannot be reversed. In this process cardiac fibroblasts are thought to be the 
mayor source of excessive ECM proteins and other factors working auto- or paracrine in the 
tissue [101].  
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Figure 2.6: Different cases of remodeling in cardiac myopathies Figure adapted from 
Heineke et al. 2006. Shown is a schematic picture of changes in ventricle size and wall 
thickness during reversible and irreversible remodeling processes. 
 
2.7 The cardiac fibroblast 
 
Fibroblasts in general can be found amongst others in the lung, heart, skin and kidney. They 
are vimentin expressing cells with mesenchymal origin whose function during embryogenesis 
is yet not fully understood. In adulthood, one of the most important roles of fibroblasts is to 
maintain the homeostasis of the extracellular matrix [102]. Most fibroblasts show certain 
common characteristics like a spindle shaped cell body in culture, the absence of a basal 
membrane and a prominent Golgi apparatus [103]. This is also in part true for cardiac 
fibroblasts which can make up to 70% of the whole heart cell content dependent on the 
species [104]. Cardiac fibroblasts are no homogenous cell population, they e.g. can originate 
from epithelial cells from the epicardium or evolve out of cardiac endothelial cell that undergo 
endothelial-to-mesenchymal transition like this has been shown for valvular fibroblasts [105]. 
In addition, there are also other sources like fibrocytes, which are bone marrow-derived cells 
[106]. The complexity of different origins of the cardiac fibroblasts also explains why there is 
no clear characterization possible by specific markers as the gene expression patterns of 
different fibroblast cultures tested were found to be highly divers [107].  
Electron microscopy revealed that cardiac fibroblasts are located within a three-dimensional 
network of extracellular proteins between cardiomyocytes. There, they contribute to the 
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structural, mechanical and electric properties in the healthy heart by regulating the ECM and 
probably functioning as conducting units. To maintain ECM homeostasis cardiac fibroblasts 
secrete components of the ECM, especially collagen I, III and fibronectin to create a scaffold 
for other cell types [108]. On the other hand they express and secret MMPs to maintain the 
balance of matrix synthesis and degradation [109]. Within this scaffold cardiac fibroblasts 
were shown to connect tightly to contracting groups of cardiomyocytes via gap junctions 
made of connexin (Cx) 43 and 45 and as well as to the ECM via integrins [110, 111]. Due to 
this network provided, fibroblasts support the distribution of contractile forces throughout the 
heart tissue [108]. In addition, cardiac fibroblasts possess a high membrane resistance which 
makes them good conductors inside the ECM which itself has more the characteristics of an 
insulator [112, 113]. It was shown in a co-culture model of rat ventricular cells that cardiac 
fibroblasts respond to the contraction of neighbor cardiomyocytes by changing their 
membrane potential and that they can even synchronize the contraction rhythm of two 
distinct cardiomyocyte populations [114]. As mentioned above, fibroblasts connect to 
contracting myocytes via ion-permeable gap junctions. In an in vivo model it was observed 
that fibroblasts express different patterns of connexins dependent on the cell-cell type 
interaction. While fibroblasts connected to each other were found to express more Cx 40, 
fibroblasts connected to cardiomyocytes expressed more Cx 45 and 43 in the rabbit 
sinoatrial node [110]. 
 
2.8 The activated fibroblasts - myofibroblasts 
 
Cardiac fibroblasts embedded in a healthy tissue are considered quiescent. Although the 
cells secrete factors at all times and participate in electric coupling their potential to migrate 
or proliferate is very low. Nevertheless, fibroblasts become activated by external stimuli like 
the overactivated renin-angiotensin-aldosterone system in heart failure or an increased cyclic 
tensile stress [105, 115, 116]. Upon activation cardiac fibroblasts start to display features of 
smooth muscle differentiation and were found to contribute to repair and remodeling 
processes in the diseased heart. After a myocardial infarct these cells can also be found in 
the scar area [117] 
Where these transformed fibroblasts, also called myofibroblasts due to their smooth muscle 
characteristics, originate from is still not clear. By fate-mapping experiments they were 
shown to originate out of quiescent fibroblasts but also out of epithelial-like cell undergoing 
epithelial-mesenchymal transition (EMT) [118]. Another source are leukocytes, in particular 
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fibrocytes from the bone marrow, as well as endothelial cells from blood vessels and 
pericytes which are α-sm-actin positive cells [119].  
 
Figure 2.7: Sources of myofibroblasts Figure adapted from Davis et al. 2014. Shown are 
sources of myofibroblasts which are mobilized during acute remodeling (left box) and during 
chronic injury (right boxes). 
In the scenario of a myocardial infarction cardiac fibroblasts were found to transform in two 
steps: first a proto-myofibroblast is created which develops strong stress fibers. In addition, 
they show a fast focal adhesion site turnover which makes it easier for the activated 
fibroblast to migrate towards the damaged area [120]. As soon as the cells arrive at the 
damaged area, they initiate the second phase secreting ECM proteins and inflammatory 
factors. To built-up a scar tissue the cells start to express α-sm-actin to support stress fibers 
and develop a strong contractile phenotype that is important for closing the wound and 
preventing the rupture of the ventricular wall [120]. In addition, the activated fibroblasts 
increase the secretion of collagen I and III and also of ECM-degrading MMPs [121]. The 
secretion of MMPs enables the myofibroblasts to migrate within the scar tissue to the side of 
repair by degrading ECM proteins in their path [83]. The deposition of collagens leads to a 
stiffening of the tissue at the site of repair supporting the closed wound and thus to reparative 
fibrosis. The equilibrium of constant matrix deposition and degradation that exists in a 
healthy heart is therefore shifted in pathological remodeling by myofibroblasts towards the 
production of ECM components [122].  
Besides secreting MMPs and key proteins of the ECM, fibroblasts are also a source of 
bioactive molecules in the heart. After injury, a pro-inflammatory environment is generated by 
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the secretion of cytokines and interleukins and by the recruitment of neutrophils and 
macrophages that clear the area from dead cells and debris [123]. The tumor necrosis factor-
α (TNF-α), interleukins like IL-1β and IL-6 and the transforming growth factor-β (TGF-β) were 
found to be secreted by activated cardiac fibroblasts upon acute remodeling. These factors 
were shown to act in a paracrine and autocrine fashion [124]. TNF-α not only induced 
myofibroblast invasion, MMP secretion and proliferation but also the secretion of IL-1β and 
IL-6 [125]. Cardiomyocytes were found to respond to IL-6 secreted by myofibroblasts as a 
paracrine stimulus that contributed to hypertrophic cardiomyocyte growth [126]. TGF-β was 
identified as a locally generated cytokine that induces the transformation of quiescent 
fibroblasts into myofibroblasts and therefore promotes proliferation, migration, apoptosis as 
well as ECM production [124]. The induction of fibroblast transformation by TGF-β in the 
early stages of MI have been proven to be beneficial. However, a continuously high level of 
this cytokine in the scar area contributed to an excessive deposition of ECM components 
[115]. In general, the increase in ECM deposition leads to an impaired contractile 
performance of the heart by stiffening of the ventricular wall, irreversible fibrosis and 
increases the risk of arrhythmias [127].  
After scar maturation an unknown number of myofibroblasts undergoes apoptosis while 
some still stay located in the collagen-rich network they produced [128]. The fate of these 
activated cells inside the scar long after maturation is not well investigated. It is believed that 
the remaining cells continue to reinforce the tissue with further collagen deposition as an 
adaptive response to further hemodynamic stress [129]  
 
2.9 RhoA and its effectors in the heart 
 
A variety of in vitro and in vivo studies have been performed to investigate the role of RhoA, 
its activators, inhibitors and effectors in the heart with the main focus on cardiomyocytes. On 
a cellular level RhoA was initially connected to a hypertrophic response in these cells 
induced by factors like endothelin-1, Ang II and the α1-adrenoceptor agonist phenylephrine 
[130-132]. Early studies showed that the inhibition of RhoA and ROCK reduced the 
expression of hypertrophy-associated proteins like of the atrial natriuretic factor (ANF) and of 
the α-myosin heavy chain [133, 134].  
 




Figure 2.8: Role of Rho-associated kinases (ROCKs) in cardiovascular diseases 
Scheme modified from Noma et al. 2006. Cardiovascular diseases which involve the RhoA-
ROCK pathway are depicted.  
 
In vivo the RhoA pathway was found to be activated in a number of cardiac disease models. 
For example, after transverse aortic constriction (TAC) RhoA was shown to be strongly 
activated shortly after surgery in mice [135]. In a rat model of diabetic cardiomyopathy it 
could be demonstrated that not only the activation of RhoA was increased but also its 
expression [136], and in a rat model of hypertension-induced heart failure ROCK2 was found 
to be increased in the membrane fraction of the heart [137]. Most of these models suggest 
that an induction of the RhoA/ROCK pathway is detrimental for the heart as the inhibition of 
RhoA activation e.g. by statins [33, 138] or the inhibition of ROCK [139] could prevent the 
remodeling of the hearts. In line with this idea of a disease-driving pathway were also the 
results of most studies with genetic RhoA/ROCK models. Sah and colleagues demonstrated 
in 1999 that the cardiomyocyte-specific overexpression of wild type RhoA had a clear 
negative influence on the performance of the heart. These hearts did not show a 
hypertrophic phenotype as hypothesized from in vitro data, but a strong interstitial fibrosis 
and ventricular dilation. In electrocardiography, bradycardia, and atrioventricular blocks were 
observed. Overall the mice had severe edema and the survival was strongly impaired [140]. 
In accordance, it has been shown that in haplodeficient ROCK1(+/-) mice the degree of 
cardiac fibrosis was reduced after Ang II-infusion, TAC and myocardial infarction [141]. A 
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recent study, then again raised the idea of a contribution of this pathway in cardiac 
hypertrophy as the specific deletion of ROCK2 in cardiomyocytes resulted in a reduction in 
cardiomyocyte hypertrophy after Ang II infusion [142]. 
In contrast, other models support the hypothesis that the RhoA pathway has at least some 
beneficial aspects in heart diseases. By inhibiting the activation of RhoA, Rac1 and Cdc42 by 
a cardiomyocyte-specific overexpression of RhoGDI unexpectedly the same phenotype was 
found as in the RhoA-transgenic mice including the AV conduction defect [143]. This might 
be explained by the unselective inhibition of diverse GTPases. But in addition, a beneficial 
function of RhoA was shown in a model of ischemia/reperfusion in mice. The transgenic 
animals expressed a doxycycline-inducible, cardiomyocyte-specific, constitutively active form 
of RhoA. After ischemia caused by ligation of the left anterior descending artery the vessel 
was reopened again to induce reperfusion. Animals, expressing the active form of RhoA, 
showed in a comparable area at risk a reduction in infarct size by 70% compared to control. 
This data argues for a cardioprotective effect of RhoA in the heart [144]. 
Compared to cardiomyocytes only few data is available on the role of RhoA in cardiac 
fibroblasts, especially on its impact on myofibroblast characteristics. Recently, the 
differentiation into myofibroblasts, involving the secretion of fibrotic markers like collagen I, 
TGF-β   and  CTGF, as well as the migration performance were found reduced upon 
downregulation of RhoA in rat ventricular fibroblasts [53]. In addition, atrial fibroblasts with 
lower levels of active RhoA showed a decrease in their proliferation rate in vitro [93]. One of 
the main reasons for this lack of knowledge on RhoA in cardiac fibroblasts is that there is no 
genetic model available allowing the specific knockout or overexpression of a certain gene in 
this cell type. 
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3  Aim of the thesis  
 
The aim of this thesis was to investigate the role of RhoA in cardiac fibroblasts. For this 
neonatal rat cardiac fibroblasts were isolated and RhoA expression reduced via lentiviral-
mediated shRNA expression. Then, the impact on protein expression, cell morphology as 
well as adhesion velocity was studied. Furthermore, it was evaluated whether the knockdown 
of RhoA affects the typical myofibroblast characteristics like migration, proliferation and the 
secretion of profibrotic factors. Finally, engineered tissues were generated containing 
fibroblasts with reduced RhoA expression to investigate the impact on contractile properties. 
In parallel wild type cardiac fibroblasts were treated with inhibitors of the RhoA downstream 
effectors ROCK and HDAC6 and the outcome of these experiments was compared with the 
results obtained with the knockdown model.  
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4.1.1 Devices and plastic material 
 
Device Model Company 
Agarose gel chamber Mini SUB Cell GT Bio-Rad Laboratories 
Bacteria incubator Incubator Sanyo/Panasonic  
Blot imager VersaDoc Bio-Rad Laboratories 




Cell counter Casy Counter Roche 
Cell culture centrifuge 1 Centrifuge 5804R Eppendorf 
Cell culture centrifuge 2 Megafuge 3.0R Thermo Scientific 
Combi table centrifuge with 
vortexer 
Combispin FVL 2400 N  Peqlab 
Contraction setup IOA-5301 Föhr Medical Instruments 
Gel imager GelDoc Bio-Rad Laboratories 
Incubator C200 Labotect, Göttingen 
Large scale shaker Innova 4300 Eppendorf 
Multi-mode microplate 
reader 
Flexstation 3 Molecular Devices 
Microscope filter blue 350 DAPI Olympus 
Microscope filter red 575 TxRed Olympus 
Microscope filter green 485 FITC Olympus 
Microscope objective 4x UPlanFLN4xPh Olympus 
Microscope objective 10x UPlanFLN10xPh Olympus 
Microscope objective 20x LUCPlanFLN20xPh Olympus 
Microscope objective 40x LUCPlanFLN20xPh Olympus 
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Multiparameter cell analyzer Cellavista SynenTec 
Micro volume spectro-
photometer 
Nanodrop 1000 Peqlab 
PCR machine Mastercycler gradient Eppendorf 
pH meter Inolab pH Wtw 
Power supply Power PAC HD Bio-Rad Laboratories 
Real-time PCR system  Taqman 7900 HT Life Technologies 
Rocker  Diomax 1030 Heidolph 
Rotation shaker Reax 3 Heidolph 
Rotor ultracentrifuge SW27 Beckman Coulter 
Scale Portable Sartorius 
Shaker 3016 GFL 
Shaker (4°C) Vibramax 100 Heidolph 
Special accuracy scale Research Sartorius 
Sterile workbench Telstar Bio II A Prettl 
Stimulator STI 08 Current Stimulator Föhr Medical Instruments 
Table centrifuge Centrifuge 5415D Eppendorf 
Thermomixer Thermomixer compact Eppendorf 
Ultracentrifuge L8 70M Beckman Coulter 
Vortexer VF2 W. Krannich 
Water bath 2764 Eppendorf 
Table 4.1: Devices 
 
Plastic material 
 Type Company 
Cell culture bottles T75, T175 Sarstedt 
Cell culture plates 10 cm, 15 cm Sarstedt 
Filter tips 1000 mL, 100 mL,10 mL Greiner Bio One 
Multi tips 10 mL Eppendorf 
Pipette tips 1000 mL, 100 mL,10 mL Sarstedt 
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Reaction tubes 50 mL, 15 mL, 2 mL, 1.5 mL, 
0.5 mL, 0.2 mL 
Sarstedt 
384-well plates MicroAmp optical 384-well 
reaction plate 
Life Technologies 
Centrifugation tubes Polyallomer centrifugation 
tubes, 17 mL 
Beckman 
Table 4.2: Plastic material 
 
4.1.2 Chemicals and media 
 
Reagent Company 
Acetic acid Carl Roth 
Acrylamide solution rotiphorese gel 30 Carl Roth 
Agar-agar AppliChem 
Ammonium persulfate (APS) AppliChem 
Angiotensin II (Ang II) Sigma-Aldrich 
Ascorbic acid AppliChem 
Bradford reagent (Roti-Quant) Carl Roth 
Bromophenol blue Sigma-Aldrich 
Carbenicillin AppliChem 
Chicken embryo extract (CEE) Self made 
Cesium chloride (CsCl2) AppliChem, Darmstadt 
Collagen I (rat tail) Self made 
4′,6-Diamidin-2-phenylindol (DAPI) Roche 
DMEM (1 g/L glucose, NaHCO3) Biochrom 
DMEM Glutamax (1 g/L glucose, pyruvic 
acid) 
Life Technologies 
DMEM Glutamax (4.5 g/L glucose) Life Technologies 
DMEM (powder) BD Biosciences 
DNAseI Merck 
Fetal calf serum (FCS) Life Technologies 
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FGM-3 BulletKit Lonza 
Glycerol Carl Roth 
Glycin AppliChem 
HEPES-buffered saline Lonza 
Horse serum Life Technologies 
Igepal CA-630 Sigma-Aldrich 
Kanamycin Sigma-Aldrich 
Lumi light Roche 
Matrigel BD Biosciences 
Methanol Carl Roth 
β-mercaptoethanol AppliChem 
Non-essential amino acids (NEAA) 
(100x) 
Life Technologies 
Paraformaldehyde (PFA) Sigma-Aldrich 
Phosphate-buffered saline (PBS) Life Technologies 
Penicillin/Streptomycin (PenStrep) 





Puromycin Life Technologies 
Sodium dodecyl sulfate (SDS) AppliChem 
Super signal west femto Thermo Scientific 
Tetramethylethylenediamine (TEMED) Merck 
Tryptone AppliChem 
Triton-X 100 Carl Roth 
Trypsin (powder) BD Biosciences 
Trypsin-EDTA 0.05% Life Technologies 
Trypsin/EDTA solution Lonza 
Trypsin neutralizing solution Lonza 
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Tween-20 Carl Roth 
Yeast extract AppliChem 
Table 4.3: Chemicals and media 
  




4.1.3.1 Media and buffers for cell culture 
Growth medium                                              DMEM Glutamax (4.5 g/L glucose) 
       10% FCS (active) 
       1% PenStrep 
       1% NEAA 
Serum-reduced medium    DMEM Glutamax (4.5 g/L glucose) 
       1% FCS (active) 
       1% PenStrep  
       1% NEAA 
Non-cardiomyocyte medium (NKM)   DMEM Glutamax (1 g/L glucose, pyruvic 
acid) 
       10% FCS  
       (heat inactivated at 56°C for 30 min) 
       1% PenStrep  
HEK293/TSA201 growth medium   DMEM Glutamax (4.5 g/L glucose) 
       10% FCS  
       (heat inactivated at 56°C for 30 min) 
       1% PenStrep 
HEK293/TSA201 serum-reduced medium  DMEM Glutamax (4.5 g/L glucose) 
       0.5% FCS 
       (heat inactivated at 56°C for 30 min) 
       1% PenStrep  
10 x DMEM      13.3 mg DMEM (powder) 
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       ad 10 mL with distilled H2O 
       → sterile filtered 
2 x DMEM       1 mL 10 x DMEM 
       1 mL Horse serum 
       0.2 mL CEE 
       0.1 mL PenStrep 
       ad 5 mL with distilled H2O 
2.5 x DMEM       2.5 mL 10 x DMEM 
       2.5 mL FCS (active) 
       0.25 mL PenStrep 
       ad 10 mL with distilled H2O 
       → sterile filtered 
EHM medium      DMEM (1 g/L glucose, NaHCO3) 
       11.6% Horse serum 
       2.3% CEE 
       1% PenStrep 
 
Buffers for contraction measurements and cell isolation 
CaCl2 stock      165.57 g CaCl2*2 H2O 
       ad 500 mL with distilled H2O 
MgCl2 stock      106.38 g MgCl2*6 H2O 
       ad 500 mL with distilled H2O 
Stock 1 (0.2 mM Ca2+)    175 g NaCl 
       10 g KCl 
       2.22 mL CaCl2 stock 
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       25 mL MgCl2 stock 
       ad 1 L with distilled H2O 
Stock 2      50 g NaHCO3 
       ad 1 L with distilled H2O 
Stock 3       5.8 g NaH2PO4 
       ad 1 L with distilled H2O 
Tyrode solution     40 mL Stock 1 
       38 mL Stock 2 
       10 mL Stock 3 
       1 g Glucose 
       100 mg Ascorbic acid 
       ad 1L with distilled H2O 
HEPES stock      47.66 g HEPES 
       ad 1 L with distilled H2O 
       pH 7.4 with NaOH 
       → sterile filtered 
Calcium and bicarbonate-free Hanks´   40 mL NaCl stock (3.42 M) 
with HEPES (CBFHH)    10 mL KCl stock (0.54 M) 
       10 mL MgSO4 stock (0.081 M) 
       10 mL KH2PO4 stock (0.044 M) 
       10 mL Na2HPO4*2 H2O stock (0.034 M) 
       10 mL glucose stock (0.56 M) 
       100 mL HEPES stock 
       → sterile filtered 
4.1.3.2 Media for bacterial culture 
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LB medium      10 g Tryptone 
       5 g NaCl 
       5 g Yeast extract 
       ad 1 L with distilled H2O 
       → autoclaved 
SOB medium      20 g Tryptone 
       5 g Yeast extract 
       0.5 g NaCl 
       ad 1 L with distilled H2O 
       → autoclaved 
       10 mL MgCl2 stock (10 mM) 
       10 mL MgSO4 stock (1 mM) 
Agar plates      2.8 g Agar agar 
       200 mL LB medium 
       Antibiotics: 
       50 µg/mL Carbenicillin 
       or 




Buffer for lentivirus purification 
TNE buffer      0.3 g Tris 
       0.3 g NaCl 
       7.3 mg EDTA 
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       ad 15 mL with distilled H2O 
pH 7.4 with HCl 
       → sterile filtered 
 
Buffer for adenovirus purification 
10 x VSB      12.1 g Tris 
       80 g NaCl 
       3.7 g KCl 
       0.95 g MgCl2 
       ad 1 L with distilled H2O 
       pH 7.4 with HCl 
Cesium chloride „light stock“(ρ=1.209 g/mL) 11.02 g CsCl2 
       ad 50 g with 1x VSB Buffer 
Cesium chloride „heavy stock“(ρ=1.459 g/mL) 21.1 g CsCl2 
       ad 50 g with 1 x VSB Buffer 
 
Buffer for protein biochemical methods 
10 x Tris-buffered saline (10 x TBS)   24.2 g Tris 
       175.3 g NaCl 
       ad 2 L with distilled H2O 
       pH 7.4 with HCl 
1 x Tris-buffered saline with tween-20  200 mL TBS 
(TBST)      2 mL Tween-20 
       ad 2 L with distilled H2O 
5 x SDS-PAGE electrophoresis buffer  30.2 g Tris 
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       188 g Glycine 
       10 g SDS (w/v) 
       ad 2 L with distilled H2O 
       pH 8.3 with HCl 
1 x Immunoblot buffer    6 g Tris 
       28.8 g Glycine 
       400 mL Methanol (v/v) 
       ad 2 L with distilled H2O 
       pH 8.4 
PonceauS       0.2 g PonceauS  
       3 mL Acetic acid 
       ad 100 mL with distilled H2O 
Lysis buffer (GST-Fish)    6 g Tris 
       8.8 g NaCl 
       0.4 g MgCl2 
       100 mL Glycerol (v/v) 
       10 mL Igepal CA-630 (v/v) 
       ad 1 L with distilled H2O 
       pH 7.4 with HCl 
4 x SDS loading buffer (Laemmli buffer)  50 mL Glycerol 
(with glycerol)      10 mL β-Mercaptoethanol 
       3.6 g Tris 
       5.7 g SDS 
       0.2 g Bromophenol blue 
       ad 100 mL with distilled H2O 
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       pH 7.4 with HCl 
4 x SDS Loading buffer (Laemmli buffer)  10 mL β-Mercaptoethanol  
 (without glycerol)     3.6 g Tris 
       5.7 g SDS 
       0.2 g Bromophenol blue 
       ad 100 mL with distilled H2O 












1:2000/1:500 6-11B-1 Sigma-Aldrich 
β-actin 1:7500/- AC-47 Sigma-Aldrich 
β-actin -/1:50 4C2F9H12 C. Chapponier Lab 
γ-actin -/1:50 2A3G8E2 C. Chapponier Lab 
CTGF 1:200/1:50 L-20 Santa Cruz 
HDAC6 1:1000/- D21B10 Cell Signaling 
α-smooth 
muscle actin 
1:2500/1:500 1A4 Sigma-Aldrich 
RhoA 1:200/- 26C4 Santa Cruz 
RhoC 1:1000/- D40E4 Cell Signaling 
Tubulin 1:2000/1:500 B-5-1-2 Sigma-Aldrich 
Tyrosinated 
tubulin 
1:5000/1:200 Tub-1A2 Sigma-Aldrich 
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Vimentin 1:2000/1:100 V9 Sigma-Aldrich 
Vinculin 1:2000/1:500 hVIN-1 Sigma-Aldrich 
Table 4.4: Primary antibodies 
 
Secondary antibodies for immunoblot analyses 
Secondary 
antibody 
Dilution Lot no. Company Host 
Anti-mouse-IgG-
HRP 
1:10000 031M4752 Sigma-Aldrich rabbit 
Anti-rabbit-IgG-
HRP 
1:40000 119K4815 Sigma-Aldrich goat 
Anti-goat-IgG-
HRP 
1:10000 sc-2020 Santa Cruz donkey 
Table 4.5: Secondary antibodies for immunoblot analyses 
 
Secondary antibodies for immunofluorescence analyses 
Secondary 
antibody 




















IgG1-FITC 1:50 SouthernBiotech mouse 
IgG2b-TRITC 1:50 SouthernBiotech mouse 
Table 4.6: Secondary antibodies for immunofluorescence analyses 
 
Fluorophore-conjugated phallotoxin and wheat germ agglutinin 
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Reagent Stock concentration 
(in H2O) 
Dilution Company 
TRITC-phalloidin 0.5 mg/mL  1:1000 Sigma-Aldrich 
Alexa Fluor 488-WGA 1 mg/mL 1:200 Life Technologies 
Table 4.7: Fluorophore-conjugated phallotoxin and wheat germ agglutinin 
 
4.1.6 Enzymes and Kits 
 
Application Name Company 
Total RNA preparation RNeasy mini kit Qiagen 
Plasmid DNA preparation Exprep mini kit GeneAll 
Plasmid DNA preparation Plasmid midi kit Qiagen 
Apoptosis/necrosis staining Annexin-V-FLUOS staining 
kit 
Roche 
PCR product purification High Pure PCR Product 
Purification Kit 
Roche 
DNA ligation Quick ligase kit New England Biolabs 
Table 4.8: Kits 
 
PCR 
Application Name Company 
qRT-PCR Quantifast RT-PCR SYBR 
mix 
Qiagen 
qRT-PCR Hot FirePol Eva Green 
polymerase 
Solis BioDyne 
cDNA synthesis RevertAid first strand cDNA 
synthesis kit 
Thermo Scientific 
Endpoint PCR PrimeStar HS polymerase TaKaRa 
Table 4.9: PCR enzymes 
 
Restriction enzymes 
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Enzyme Supplements Company 
BamHI - New England Biolabs 
EcoRI - New England Biolabs 
BsgI S-adenosyl methionine 
(SAM) 
New England Biolabs 
MfeI - New England Biolabs 




All primer sequences are annotated in 5´→3´ orientation. 
Protein  Sequence  
RhoA forward gca gat att gaa gtg gac ggg 
reverse tgg gat gtt ttc taa act atc agg g 
RhoB forward cat cga ctc gca caa agc ag 
reverse ata cga tgc acg gag tgt cg 
PBGD forward cct gaa act ctg ctt cgc tg 
reverse ctg gac cat ctt ctt gct gaa 
CTGF forward ccg ggt tac caa tga caa ta 
reverse cac acc cca cag aac tta gc 
HDAC6 forward agc gca gtc tta ttg atg gg 
reverse cca tgc tca tag cgg tgg at 
Venus N-terminus forward tta gga tcc atg gtg agc aag ggc gag 
reverse agc gaa ttc ggc cat gat ata gac gtt gtg gct gt 
RhoA-RBD forward gag caa ttg ctc gac tgg tcc ctg cta ga 
reverse cga gaa ttc gcg gcc gcc acc aga ttt tt 
Venus C-terminus forward gag gaa ttc gac aag cag aag aac ggc atc 
reverse ctc gaa ttc tta ctt gta cag ctc gtc cat 
Table 4.11: Primer 
 






FRET sensor pRaichu1298X  
(M. Matsuda Lab)  
[Yoshizaki et al, 2003, J. Cell. Bio.] 
Venus, RhoA-Rho binding domain of 
rhotekin (RBD) 





Vectors derived from the human immunodeficiency virus-1 (HIV-1) are a preferred system for 
gene delivery into proliferative and non-proliferative cells. This system provides a stable long-
term expression of the gene of interest by using the virus´ ability to transcribe its delivered 
RNA into DNA and randomly integrate in the cell genome. With cell division the integrated 
gene of interest is replicated and therefore inherited to the daughter cells [145]. 
To make this system particularly safe, three plasmids have to be cotransfected into host cells 
to produce lentiviral particles (table below). The first plasmid is coding for the gene of interest 
(GOI) and an antibiotic resistance gene. The second plasmid, psPAX.2, codes for the 
necessary lentiviral proteins involved in assembly of particles (Gag [146], virus replication 
and pathogenesis (Nef [147]) as well as virus DNA replication (Tat [148]). Finally, pMD2.G 
encodes for the glycoprotein G of the vesicular stomatitis virus and extends the spectrum of 
cell types that can be infected by the virus particles. 
In this project the gene of interest plasmids code for shRNA which are specific for RhoA or 
control sequences. All plasmids encode in addition for a resistance gene allowing the 
selection of positive cell clones with puromycin. 
Name Plasmid  Coding for 










shScr pLKO.1 shRNA, no fit to any mammal gene, 
CCTAAGGTTAAGTCGCCCTCG 
Sigma-Aldrich 
psPAX.2 psPAX.2 Lentiviral proteins (Gag, Rev, Tat) D. Trono Lab 
pMD2.G pMD2.G Glycoprotein of the human vesicular stomatitis 
virus  
D. Trono Lab 
Table 4.13: Lentivirus plasmids 
 
Adenovirus 
For live cell imaging the LifeAct GFP-tagged adenovirus provided by Ibidi was used. 
The LifeAct fusion protein consists of a 17 amino acid actin binding domain fused to GFP 
and is described to have no interference with actin dynamics. Therefore it is highly suitable 
for live cell imaging [149]. 
 
4.1.10 Cells and bacteria 
 
Cells 
Name Organism Source, Note 
Neonatal rat cardiac 
fibroblasts 
rat Heart ventricular tissue, 
primary cells 
Normal human cardiac 
fibroblasts (NHCF-V) 
human Heart ventricular tissue 
Donor: male, 50 years, 
caucasian, no heart disease 
HEK293A human Embryonic kidney, 
immortalized by an 
adenovirus serotype 5 
Tsa201 human Embryonic kidney, 
immortalized by SV40 large 
T-antigen 
Table 4.14: Cells 
 
Bacteria 
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For cloning chemically competent MAX Efficiency DH10B bacteria provided by Life 
Technologies were used. 
Genotype: F- mcrA Δ(mrr-hsdRMS-mcrBC) Φ80dlacZΔM15 ΔlacX74 endA1 recA1 deoR 





Immunoblot Quantity One 
Immunofluorescence/life cell imaging Xcellence pro 
Migration assay ImageJ  
Plug-in: manual tracking, chemotaxis assay 
Golgi size and density analyses ImageJ 
Plug-in: analyze particles 
qRT-PCR SDS 2.4 
Contraction measurement BeMon32 
Contraction measurement analyses Amon32 
Proliferation-DAPI-assay CellaVista 
Multi-mode microplate reader measurements SoftMax Pro 5.4 
Statistical evaluations Graphpad Prism 
Table 4.15: Software 
 
  




4.2.1 Cell biological methods 
 
4.2.1.1 Neonatal rat cardiac fibroblast isolation 
 
Cardiac fibroblasts were isolated from neonatal rats (day 0 to 3) by using a modified cell 
isolation protocol established by Simpson et al.[110]. 
The complete hearts were taken out and the atria were removed. The ventricles were cut into 
pieces of 1-2 mm size and washed twice with CBFHH. The tissue was dissociated over 4 h 
by alternating treatments with trypsin and DNAseI solutions in CBFHH at room temperature 
during continuous agitation or gentle pipetting, respectively. The first supernatant was 
discarded, the ones of the following step after trypsin and DNAseI treatments were collected 
upon clouding of the supernatant (1-4 min) till no cells dissolved from the tissue anymore. 
After centrifugation at 60 g for 15 min at 4°C the cells were pooled and washed with ice-cold 
NKM. After one last DNAseI treatment the cells were centrifuged, pooled and strained with a 
mesh of stainless steel (250  µm pores). The cells were counted in trypan blue solution (1:1, 
0.4%) to determine the cell number and the amount of cell death.  
 
4.2.1.2 Cardiac fibroblast/cardiomyocyte separation 
 
For cell separation 107 cells in suspension were seeded on a 15 cm cell culture dish in ice-
cold NKM. After 60 min of incubation at 37°C, 5% CO2, the NKM containing the majority of 
cardiomyocytes was collected and the medium was changed to prewarmed growth medium. 
For the next 6 days the medium was changed every day to wash off cell debris and 
unattached cardiomyocytes. The cardiac fibroblasts were cultures until they reached full 
confluency. 
 
4.2.1.3 Cell cultivation and passaging 
 
All cells were cultured in the respective growth medium in a water steam-saturated cell 
culture incubator at 37°C and 5% CO2.  
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For passaging, NRCF were rinsed with an appropriate volume of prewarmed PBS and 
treated with trypsin (0.05%, trypsin-EDTA) for cell detachment. After 3-4 min incubation at 
37°C, 5% CO2, the detachment of the fibroblast was controlled with a light microscope. The 
trypsin was deactivated by adding 2 volumes of growth medium. The cells were harvested 
and centrifuged at 1000 g at 4°C for 2 min. The supernatant was discarded and the cells 
were resuspended in growth medium, then counted and seeded in the required density.  
For TSA and HEK293 cells the same protocol was applied but incubation time of the trypsin 
step was shortened to 2 min at room temperature. 
 
4.2.1.4 Lentivirus production 
 
Tsa201 cells were cultured on 10 cm dishes in growth medium until confluency of 70% was 
reached. After washing with PBS the conditions were changed to serum-reduced medium. 
Transfection was performed strictly according to the polyfect transfection reagent handbook 
provided by Qiagen. 
Plasmid with GOI  3 µg 
psPAX.2 3 µg 
pMD2.G 2 µg 
Medium without antibiotics or serum 300 µL 
Polyfect 80 µL 
Serum-reduced medium 620 µL 
Serum-reduced medium to cells 7 mL 
Total volume 8 mL 
   Table 4.16: Transfection mixture for 10 cm culture dish 
After 48 and 72 h the virus particle-containing supernatants were harvested and if required 
fresh serum-reduced medium was added. The collected supernatants were pooled and 
filtered through a 45 µm syringe filter to remove cell debris.  
 
4 Material and Methods 
43 
4.2.1.5 Lentivirus purification 
 
The concentration and purification of lentiviral particles reduces the possibility of 
contamination and removes the, for primary cells potentially harmful, host cell debris. Plus 
the lentiviral particles can be stored in solution at -80°C for month in a space-saving fashion.  
The harvested supernatants containing lentiviral particles were filled in 17 mL plastic 
centrifuge tubes and carefully underlayed with 1 mL 20% sucrose solution in TNE buffer. 
After centrifugation for 4 h at 22000 g and 4°C the lentiviral particles were found in and on 
the sucrose cushions. The overlaying supernatants were discarded and the concentrated 
viruses were mixed, aliquoted, instantly frozen in liquid nitrogen, and stored at -80°C. 
 
4.2.1.6 Lentiviral infection of NRCF 
 
Wild type fibroblasts were passaged according to 4.2.1.3 and seeded in growth medium 
containing 8 µg/mL polybrene to improve the infection rate. Virus particles were thawed on 
ice and added to the medium in the culture vessel. After culturing the cells for 48 h at 37°C, 
5% CO2, the medium was changed to selection medium containing 1 µg/mL puromycin. The 
selection of the lentiviral-infected fibroblasts was performed for up to 12 days. Selection 
conditions were maintained also in case of further passaging. The RhoA knockdown was 
controlled by immunoblot. 
 
4.2.1.7 Amplification of Adenoviruses 
 
LifeAct adenoviral particles were purchased from Ibidi and then amplified as described in the 
following. HEK293A in serum-reduced medium were infected with adenovirus particles and 
incubated at 37°C, 5% CO2 until cells show a clear GFP expression and start to detach. The 
cells were harvested, and for lysis the suspension was frozen in liquid nitrogen, then again 
thawed at 37°C in a water bath. This procedure was repeated three times. To pellet cell 
debris, the lysed cells were centrifuged at 1000 g for 5 min. The supernatant was then 
supplemented with serum-reduced medium and transferred to a new plate of 70% confluent 
HEK2983A cells. Starting from a 10 cm culture dish the virus was amplified up to 20 x 15 cm 
dishes. In the final step, the cells were harvested by gentle rinsing as soon as GFP 
expression was clearly detectable but no cell lysis was observed. The cells suspension was 
centrifuged at 1000 g for 5 min and the cell pellet was carefully washed with 50 mL PBS. 
After centrifugation at 1000 g for 5 min and resuspension in 10 mL PBS, the cells were lysed 
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as described above. The virus particles in the supernatant were separated from empty 
capsids and concentrated by cesium chloride gradient. To generate the cesium chloride 
gradient, 5 mL of the cesium chloride “light stock” was underlayed with 5 mL of the “heavy 
stock”. The harvested and washed virus particles in PBS were pipette on top and the 
gradient was centrifuged in an ultracentrifuge for 20 h, at 22000 g and 4°C. 
During centrifugation the virus particles manifested as a defined layer between the two 
cesium chloride phases and were harvested by puncturing the centrifuge tube wall with a 
needle. The obtained virus was frozen in 45% glycerol and stored at -20°C in aliquots. 
 
4.2.1.8 Casting of engineered heart muscle (EHM) 
 
A suspension of 2*106 cardiac cells isolated as described in 4.2.1.1 was supplemented with 
0.5*106 lentiviral-infected and selected cardiac fibroblasts. The cells were mixed with 
collagen type I (rat tail) and a basement membrane protein mixture (Matrigel) to provide a 
scaffold in the condensed tissues. 
Reagent Volume 
Collagen I (4.2 mg/mL) 847 µL 
2 x DMEM 847 µL 
NaOH (0.1 N) 184 µL 
Matrigel 400 µL 
Cell suspension (2.5*106 cells) 1722 µL 
Total 1 mL/ mold 
 Table 4.17: Master mixture for 4 EHMs 
The EHM mixtures were casted into silicon molds of 3.5 cm diameter and incubated at 37°C, 
5% CO2 for 1 h. The molds were then filled with EHM medium. The EHMs were cultured for 7 
days with medium changes on day 1, 3 and 5 and then transferred onto a phasic stretcher. 
For 24 h the EHMs were stretched at 1 Hz, later at 2 Hz for 6 days. Contraction 
measurements were performed 14 days after casting. 
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4.2.1.9 Contraction measurements of engineered heart muscle 
 
The contraction measurement setup was filled with tyrode solution containing 0.2 mM Ca2+ 
and the EHMs were mounted on hooks attached to the highly sensitive force meter in the 
organ baths. The calcium concentration was adjusted to 0.4 mM and the EHMs were paced 
at 2 Hz for synchronic contraction. To reach the maximal length (Lmax) as defined by Frank 
Starling, the EHMs were stepwise equally stretched every 5 min. As soon as Lmax was 
reached, the pacing was stopped, the buffer was changed and the rings were equilibrated for 
30 min in tyrode solution. After systolic and diastolic forces reached back to the baseline the 
buffer was changed again. To determine contraction force at different calcium 
concentrations, a calcium chloride stock solution (0.2 M) was stepwise added to the organ 
baths. In intervals of 10 min the calcium concentration was elevated from 0.2 mM to a final 
concentration of 3.2 mM. The systolic and diastolic forces of the paced EHMs were 
documented. After measurement the EHMs were frozen in liquid nitrogen for protein 
isolation.  
 
4.2.1.10 Protein isolation from EHMs 
 
The deep-frozen EHM tissues were ground with a pestle in a liquid nitrogen-cooled metal 
block and transferred into 1.5 mL reaction tubes containing GST-Fish buffer (200 µL/tissue). 
After incubation on ice for 15 min the samples were mixed, centrifuged at 16000 g, 4°C, 
10 min and the lysates separated from the particulate fractions for further analyses by 
immunoblot. 
 
4.2.1.11 Annexin-V-FLUOS/propidium iodide staining 
 
To identify apoptotic and necrotic cells in culture the Annexin-V-FLUOS staining kit from 
Roche was used. In brief, infected and selected fibroblasts were seeded on a 12-well plate at 
30% confluency. The Annexin-V-FLUOS and propidium iodide solution were mixed in 2 mL 
incubation buffer according to the manufacturer’s protocol. The growth medium was 
removed, the cells washed with prewarmed PBS and incubated with the staining solution for 
15 min at room temperature in the dark. Then, the cells were imaged with an inverted 
fluorescence microscope and the percentage of green (apoptosis) and green/red (necrosis) 
cells were evaluated.  
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4.2.1.12 Phalloidin staining of the actin cytoskeleton 
 
The infected and selected cells were fixed with 4% paraformaldehyde in PBS, washed twice 
with PBS, and the membranes were permeabilized with 0.05% Triton X-100 in PBS for 3 min. 
After 3 washing steps the fixed cells were incubated in a blocking solution (1x Immunoblock 
in distilled H2O) for 1 h at room temperature. TRITC-tagged phalloidin was used at a 
concentration of 0.5 µg/mL in PBS and incubated for 1 h at room temperature in combination 
with 1 µg/mL DAPI in the dark. The cells were again washed twice with PBS and then stored 




The infected and selected cells were fixed, washed, permeabilized and blocked as described 
in 4.2.1.12. Then, the cells were incubated with the primary antibody solution at its 
corresponding concentration according to table 4.4 at 4°C overnight. Afterwards, the cells 
were washed with PBS and incubated with the fluorophore-tagged secondary antibody in the 
appropriate concentration for 1 h at room temperature in the dark. The cells were again 
washed twice with PBS, then stored protected from light at 4°. 
 
4.2.1.14 Evaluation of Golgi size and density by ImageJ 
 
High resolution grey-scale images of wheat germ agglutinin (WGA)-stained Golgi 
membranes were analyzed with the ImageJ particle analysis software. In brief, the images 
were transformed into an 8 bit format, inverted and the Golgi area encircled. In this region, 
the threshold was adjusted and a binary image of the Golgi membrane stacks was 
generated. From this the complete area containing Golgi stacks was determined and by 
using the command “Analyze Particles” the membrane fraction was also determined. The 
real sizes of both areas were then calculated with the help of the microscope settings and the 
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4.2.1.15 Adhesion assay 
 
The infected and selected cells were seeded in growth medium on uncoated 12-well plates 
or plates which were coated before with 1% rat tail collagen I in PBS. After every 15 min up 
to 1 h ten images per virus type were randomly taken. The adherent and non-adherent cells 
were counted and compared relative to the total cell number.  
 
4.2.1.16 2D-Migration assay 
 
Wild type or infected and selected fibroblasts were seeded on 24-well plates and infected 
with LifeAct adenovirus stock (around 5 µL, approx. multiplicity of infection 500) for 24 h, then 
incubated with the respective inhibitors at 37°C, 5% CO2 or just kept in growth medium for 
another day. Imaging was performed in growth medium with an inverted fluorescence 
microscope equipped with a climate chamber at 37°C, 5% CO2 for 24 h. Every 20 min the 
cells were imaged in the GFP channel. Cell tracking was performed with the manual tracking 
macro in ImageJ. The average velocities and the absolute distances were calculated using 
the chemotaxis plug-in for ImageJ provided by Ibidi.  
 
4.2.1.17 Amoeboid migration assay 
 
For amoeboid migration analysis, cell culture inserts with a porous membrane on the bottom 
with randomly distributed 8 µm pores were used from Greiner Bio One (thincerts). 
Thincerts were inserted into a 24-well plate and filled with high serum or serum-reduced 
medium. Per cavity 5000 infected and selected cardiac fibroblasts or wild type cardiac 
fibroblasts with the respective inhibitors were seeded and incubated for 24 h at 37°C and 5% 
CO2. The thincerts were then washed with PBS and the cells fixed for 15 min in 4% 
paraformaldehyde in PBS. After removing the paraformaldehyde and two washing steps with 
PBS, the remaining cells were carefully removed from the membrane surfaces using a cotton 
swap. The membrane was cut out of the plastic frame with a scalpel, placed on a microscope 
slide and incubated with 10 µg/mL Hoechst 33342 in PBS for 30 min. For evaluation, the 
cells found in the pores of the membrane were visualized by fluorescence microscopy and 
counted. 
 




The proliferation of cells was determined over a time course of 4 days. In brief, the infected 
and selected cells were seeded on a 96-well plate with 5000 cells per cavity. For every time 
point cells were fixed with 4% paraformaldehyde in PBS and washed twice with PBS. The 
membranes were permeabilized with 0.05% Triton X-100 in PBS for 3 min and again washed 
three times. After incubation with 1 µg/mL DAPI in PBS for 30 min at room temperature in the 
dark the cell numbers were evaluated using the Cellavista system. 
 
4.2.1.19 Rho activity binding assay-pulldown assay 
 
The infected and selected fibroblasts were seeded on 10 cm cell culture dishes. After 24 h 
the medium was changes to low serum conditions for another day. Then, the cells were kept 
on a heating plate at 37°C and stimulated with 100 nM Angiotensin II for 30 seconds. 
Afterwards, the medium was immediately discarded and the plates were put on ice. From this 
step on, the complete assay was performed at 4°C in the cold room. The cells were lysed 
with 500 µL ice-cold GST-Fish buffer, scraped of the plate and the debris was pelletized by 
centrifugation for 2 min at 16000 g. To determine total RhoA expression 50 µL of the 
supernatants were stored separately on ice. The remaining lysate was incubated with the 
GST-Rho-binding domain of rhotekin (RBD)-fusion protein bound to glutathione sepharose 
which exclusively binds the active forms of RhoA-C. The mixture was then incubated for 1 h 
on ice in a rotating shaker. Then, the sepharose was separated from the lysates by 
centrifugation for 2 min at 16000 g. The supernatant was removed and the sepharose 
washed twice with GST-Fish buffer. The sepharose and the stored lysates were mixed with 
4x loading buffer with and without glycerol, respectively. The samples were heated up to 
95°C for 5 min. Analysis of the total and the activated amount of RhoA was then performed 
via immunoblot analyses.  
 
4.2.2 Molecular biological methods 
 
4.2.2.1 Quantitative real time PCR (qRT-PCR) 
 
Total RNA was isolated from 1*106 infected and selected fibroblasts using the RNeasy kit 
and dissolved in 50 µL RNAse-free H2O. The concentration was determined using a micro 
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volume spectrophotometer. cDNA was synthesized from 150 ng of total RNA using the 
ReverseAid First Strand cDNA synthesis according to manufacturer’s protocol. The cDNA 
was diluted 1:20 with RNAse-free H2O for qRT-PCR analysis. 
All runs of qRT-PCR were performed in a 384-well plate with the following reaction mixture 
composition: 
Component Volume 
cDNA (diluted 1:20) 1 µL 
Primer forward (10 µM) 1 µL 
Primer reverse (10 µM) 1 µL 
Quantifast RT-PCR SYBR Mix or Hot FirePol 
Eva Green Polymerase 
5 µL or 4 µL 
Nuclease-free water 2 µL /13 µL 
Total 10 µL/20 µL 
Table 4.18: qRT-PCR mixture 
The following PCR conditions were used: 
Cycle Temperature Time Number of Cycles 
Initial Denaturation 95°C 15 min 1 
Denaturation 95°C 15 sec 40 
Annealing 60°C 20 sec 40 
Extension 72°C 40 sec 40 
Denaturation 95°C 15 sec 1 
Melting curve start 
Ramp rate: 1.6°C/s 
60°C 15 sec 1 
Melting curve end 95°C 15 sec 1 
Table 4.19: qRT-PCR protocol 
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Samples were run in quadruplicates each using the primers listed above in table 4.11. The 
data was calculated using a standard curve with the following cDNA dilutions of a reference 
cDNA: 1:10, 1:30, 1:100, 1:300. The values were normalized to PBGD as a housekeeping 
gene. 
 
4.2.2.2. End point polymerase chain reaction (PCR) 
 
DNA amplification was performed using the proof reading, hot start Prime Star polymerase 
provided by TaKaRa.  
Component Volume 
5 x Prime Star Buffer 10 µL 
dNTP Mix (2.5 mM each) 4 µL 
Primer start/end (10 µM) 1 µL each 
Template DNA - pRaichu-1298X 100 ng 
Prime Star Hot Start Polymerase 0.5 µL 
Nuclease-free H2O Up to 50 µL 
Table 4.20: PCR mixture 
 
Cycle Temperature Time Number of Cycles 
Initial Denaturation 95°C 15 min 1 
Denaturation 95°C 10 sec 30 
Annealing 55°C 15 sec 30 
Extension (1 min/kb) 72°C 25 sec 30 
Final extension 72°C 10 min 1 
Table 4.21: PCR protocol 
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4.2.2.3. Cloning strategy 
 
The BiFC sensor fusion protein was generated in three cloning steps: 
Strategy: 
 
Figure 3.1: Cloning strategy 
The N-terminus of Venus was amplified by PCR adding BamHI and EcoRI restriction sites at 
the end of the forward and reverse primers, respectively. The obtained fragment was then 
cloned in the pcDNA3.1(+)-Zeo vector. In the next step, the plasmid was reopened by 
restriction digest with EcoRI and ligated with the PCR-amplified RhoA-RBD insert. This insert 
contained additional MfeI and EcoRI restriction sites inserted by PCR at the 5’ and 3’ ends, 
respectively. The ligation of the MfeI and the EcoRI site disabled the EcoRI recognition 
sequence and allowed to reopen the plasmid again with EcoRI. In the last step the C-
terminus of Venus was amplified with primers containing both EcoRI sites at the end and the 
resulting fragment was finally ligated in the plasmid.  
 
4.2.2.4 Restriction Digest 
 
The DNA was dissolved in distilled H2O completed with the appropriate reaction buffer. After 
mixing with the restriction enzyme the solution was shortly centrifuged and incubated at 37°C 
for at least 2 h. Restriction enzymes were inactivated at 65°C for 20 min. The DNA was then 




50 ng of linearized vector DNA in distilled H2O was mixed with 150 ng of insert-DNA and 
adjusted with H2O to 10 µL. Then 10 µL ligation buffer and T4 ligase (1 µL) were added, the 
solution was incubated for 1 h at room temperature, and stored at -20°C or transformed 
immediately. 




Chemically competent DH10B bacteria were thawed on ice and incubated with 7 µL of the 
ligation mixture for 30 min. The bacteria were then heat shocked in a thin wall 15 mL reaction 
tube at 42°C for 1 min and instantly put on ice for another 2 min. After mixing with 500 µL 
prewarmed SOB medium, the suspension was spread on a preheated agar plate and 
incubated overnight at 37°C. 
 
4.2.2.7 DNA isolation 
 
For DNA isolation single bacteria colonies from agar plates were picked and cultured in 3 mL 
or 150 mL of LB-medium overnight in a shaker at 37°C. 
Small scale and medium scale plasmid preparation were performed with kits according to the 
manufacturer´s protocols. The DNA concentration was determined using a micro volume 
spectrophotometer. 
 
4.2.3 Protein chemical methods 
 
4.2.3.1. Preparation of protein samples for SDS-PAGE 
 
Fibroblasts were washed with PBS, lysed and scraped off using an adequate volume of 
GST-Fish buffer. The homogenates were incubated on ice for 15 min, mixed and centrifuged 
at 4°C for 10 min at 16000 g. The supernatants containing the cell lysates were separated 
from the particulate fractions which were then frozen in liquid nitrogen and stored at -20°C. 
The lysates were kept on ice for determination of protein concentrations by Bradford assay. 
To prepare SDS-PAGE samples, 4x SDS loading buffer without glycerol was added to cell 
lysates and incubated at 95°C for 5 min for protein denaturation. 
 
4.2.3.2. Bradford assay 
 
The concentration of total protein in cell lysate samples was determined using a colorimetric 
protein assay by Bradford [150] 
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The relevant samples and a standard curve with increasing protein amounts (0, 0.4, 0.8, 1.2, 
1.6, 2.0 µg BSA) were prepared in 50 µL distilled H2O. Into every cavity 200 µL of 
1x Bradford reagent (Coomassie Brilliant Blue-G250) in H2O was added and incubated for 5 
min at room temperature. The absorbance at 595 nm was detected with a microplate reader 
and the total protein concentrations of the samples were calculated. 
 
4.2.3.3. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
 
For analysis of protein expression in total cell lysates discontinuous SDS-PAGE was 
performed. Gels with Tris-HCl (pH 8.8), 10% SDS as well as ammonium persulfate (APS) 
and tetramethylethylenediamine (TEMED) polymerization catalysts were casted containing 
the appropriate concentration of acrylamide/bisacrylamide suitable for the size of the protein 
of interest (8%-15%). Separation gels were covered with stacking gels made from 5% 
acrylamide/bisacrylamide, Tris-HCl (pH 6.8), 10% SDS, APS and TEMED. SDS-gels were 
loaded with prepared protein samples and run at 100 V for sample condensation and later at 




To make proteins accessible for antibody detection, they were transferred onto a 
nitrocellulose membrane by electroblotting after SDS-PAGE. Gel and membrane were 
packed between filter papers in ice-cold western blot buffer and transferred into a blotting 
chamber. During the blotting process the setup was either cooled with an ice pack or 
transferred to an ice-containing polystyrene box. After electroblotting at 100 V for 1 h, the 
membrane was removed from the blotting setup and incubated in PonceauS solution for 3 
min to visualize the transferred proteins. The membranes were then washed with TBST and 
blocked with blocking solution (1x Roti Block in distilled H2O) for 1 h at room temperature. 
After two more washing steps with TBST, incubation with the primary antibody in TBST on a 
shaker was performed overnight at 4°C. Then, the membrane was washed again three times 
and the secondary antibody tagged with horseradish-peroxidase (HRP) was applied in 
concentrations according to table 4.5 in TBST and incubated on a shaker at room 
temperature for 1 h. The protein-antibody complexes were detected using the 
chemiluminescent reagents Lumi Light or Super Signal West Femto. The signals were 
detected with a chemiluminescence imaging system and semi-quantitatively analyzed.  




All results obtained were summarized in Graph Pad Prism and given as mean±SEM. For 2-
group comparisons the t-test was used. Analyses and comparison of 3 or more groups was 
performed with one or two way analysis of variance (one or two way ANOVA). A one-sample 





5.1 Influence of RhoA on the morphology of NRCF and on the Golgi apparatus 
 
5.1.1 The lentiviral-induced knockdown is RhoA-specific 
 
To investigate the role of RhoA in neonatal rat cardiac fibroblasts (NRCF) a lentiviral-induced 
knockdown was used. For this, a RhoA-specific small hairpin construct was identified. It was 
found that after selection with puromycin the RhoA expression was reduced by 50% on the 
mRNA level and by about 75% on the protein level (Figure 5.1 A, B). As RhoA shares up to 
80% homology with its family members RhoB and RhoC possible effects of the shRNA 
construct on both isoforms were evaluated. However, neither RhoB nor RhoC were regulated 
by the shRNA construct, as could be shown by mRNA and immunoblot analyses, 
respectively (Figure 5.1 C). 
 
Figure 5.1: Analyses of RhoA, RhoB and RhoC expression in shControl and shRhoA 
NRCF A) qPCR analysis of RhoA mRNA in shControl and shRhoA NRCF (means ± SEM, 
n = 6, values were normalized to PBGD and are given relative to shControl, *p < 0.05). B) 
Representative immunoblot of RhoA in shControl, shRhoA and shScr cells and quantitative 
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analysis of RhoA expression normalized to β-actin (right). The relative changes in shRhoA 
and shScr to shControl are given (means ± SEM, n = 22, *p < 0.05). C) qPCR analysis of 
RhoB mRNA in shControl and shRhoA NRCF (means ± SEM, n= 6, values were normalized 
to PBGD and are given relative to shControl) (left). Representative immunoblot of RhoC and 
β-actin in shControl and shRhoA NRCF (middle) and quantitative analysis of RhoC 
expression normalized to β-actin (means ± SEM, n = 4) (right). The relative change in 
shRhoA to shControl is given. 
 
To determine if the lentivirally infected fibroblasts still respond to an extracellular stimulus, a 
RhoA activity assay was performed. ShControl and shRhoA NRCF were stimulated with 
100 nM angiotensin II (Ang II) for 30 sec or left untreated and the amount of RhoA-GTP was 
detected. It could be shown that in shControl NRCF RhoA was clearly activated by Ang II 
whereas in shRhoA NRCF no activation was detectable and the amount of total RhoA was 
strongly decreased. 
 
Figure 5.2: Angiotensin II-dependent RhoA activation in shRhoA and shControl NRCF 
Serum-starved shControl and shRhoA NRCF were treated with 100 nM angiotensin II for 30 
sec, lysed and RhoA-GTP was precipitated. Shown is the immunoblot analysis of RhoA-





5.1.2 RhoA knockdown disrupts the cytoskeleton and changes cell morphology 
 
In the next step the impact of the reduced RhoA expression on the cell morphology was 
analyzed. By staining of the actin cytoskeleton (Figure 5.3 A) and determination of the cell 
area and perimeter it was found that by 75% reduction in RhoA expression a 2-fold and 1.5-
fold increase in area and perimeter, respectively, could be detected compared to shControl 
NRCF (Figure 5.3 B). To further validate whether this increase was due to general cell 
growth or to a change in adhesion low voltage field resistance measurement of detached 
cells were performed, however, no change could be detected in the volume of both cell types 
(Figure 5.3 B). 
 
Figure 5.3: Evaluation of changes in cell morphology and volume of shControl and 
shRhoA NRCF A) Representative actin stainings with TRITC-phalloidin of shControl (left) 
and shRhoA (right) cells. B) Quantification of cell area (left) and perimeter (right) of shControl 
and shRhoA NRCF were performed (means ± SEM; n = 3, at least 50 cells per condition and 
experiment were analyzed, *p < 0.05). C) Cell volume of detached shControl and shRhoA 
NRCF were measured by resistance in a pulsed low voltage field. The relative change of 
shRhoA NRCF volume compared to shControl is given (means ± SEM, n = 5).  
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5.1.3 Reduction of RhoA influences cytoskeletal protein expression 
 
Since RhoA is known to be a strong regulator of the cytoskeleton, the expression of proteins 
found in actin filaments, intermediate filaments and microtubules was investigated by 
immunoblot analyses (Figure 5.5 A). 
 
Figure 5.4: Immunoblot analyses of changes in cytoskeletal protein expression and 
modification A) Representative immunoblots of cytoskeletal proteins in shControl and 
shRhoA NRCF lysates are shown. B) Quantification of β-actin expression in equal amounts 
of total cell lysates (left) and normalized to histone H3 (H3) (right) is shown. The relative 
changes in shRhoA versus shControl are given (means ± SEM, n = 7). C) Quantification of α-
sm-actin expression in shRhoA NRCF normalized to β-actin and given relative to shControl 
NRCF is shown (means ± SEM, n = 7, *p < 0.05). D) Quantification of acetylated tubulin in 
shRhoA NRCF normalized to total tubulin and given relative to shControl NRCF is shown 
(means ± SEM, n = 12, *p < 0.05). 
 
First, it was determined whether β-actin is a proper loading control for immunoblot analyses 
by quantification of β-actin expression in relation to the total amount of analyzed cell lysates 
and by normalization to histone H3 expression. In neither case a change in β-actin 
expression in shRhoA NRCF could be detected (Figure 5.5 B). By using then β-actin as a 
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loading control, it could be shown that the myofibroblast marker α-smooth-muscle actin (α-
sm-actin) was downregulated by 43% in shRhoA NRCF (Figure 5.5 C). In addition, the post-
translationally modified acetylated tubulin was increased by 50% (Figure 5.5 D) while all 
other analyzed proteins like γ-actin, vimentin, tubulin and the tyrosine-modified tubulin were 
found unchanged (Figure 5.5 A).  
To validate whether the increase in the acetylated tubulin fraction in shRhoA NRCF was due 
to a change in the expression of the main tubulin-deacetylase HDAC6, qPCR and 
immunoblot analyses were performed. In both cases changes could be detected neither on 
the mRNA nor on the protein levels (Figure 5.5).  
 
Figure 5.5: Evaluation of HDAC6 expression on in shRhoA and shControl NRCF Left: 
qPCR analysis of HDAC6 mRNA in shControl and shRhoA NRCF (means ± SEM, n = 6, 
values were normalized to PBGD and are given relative to shControl). Right: Quantification 
of immunoblot analysis of HDAC6 protein normalized to β-actin in shRhoA NRCF compared 
to shControl is given (means ± SEM, n = 4).  
To determine whether other proteins showed a different acetylation level in shRhoA 
compared to shControl NRCF an immunoblot was performed using an anti-acetylated-lysine 
antibody. In this experiment both the cell lysates and the particulate fractions were analyzed. 





Figure 5.6: Analysis of protein acetylation in the particulate and soluble fractions of 
shRhoA and shControl NRCF Immunoblot analysis of the protein acetylation pattern in 
soluble and particulate fractions of whole cell homogenates from shControl and shRhoA 
NRCF were performed. Shown are the ponceauS stainings and the corresponding 
immunoblots using an anti-acetyl-lysine antibody. The arrow marks the size of tubulin. 
 
5.1.4 Actin structures of higher order are reduced in RhoA knockdown cells 
 
In various cell types i.e. embryonic fibroblasts or HeLa cells, RhoA was connected to the 
assembly and turnover of cytoskeletal actin structures, especially stress fibers. In NRCF the 
knockdown of RhoA caused not only a reduction in stress fiber formation but also in other 
higher order actin structures like geodesic domes. Quantification of geodesic domes in 
shControl and shRhoA showed a significant lower number of cells carrying this highly 





Figure 5.7: Evaluation of geodesic dome structures in shRhoA and shControl NRCF 
Left: The numbers of geodesic (G), mixed (M) and non-geodesic (NG) cells were evaluated 
in shRhoA and shControl NRCF and are given as relative changes in percent of the total cell 
number (means ± SEM; n = 3, at least 50 cells per condition and experiment were analyzed, 
*p < 0.05). Right: Representative TRITC-phalloidin stainings of actin structures in shControl 
and shRhoA NRCF are shown.  
 
5.1.5 Localization of cytoskeletal proteins is not altered in lentiviral-infected NRCF 
 
To further analyze whether a rearrangement of the different actin isoforms could be detected 
in shRhoA NRCF, isoform-specific antibodies were used for immunofluorescence analysis. 
As shown in Figure 5.8 both β- and γ- actin showed a changed organization in shRhoA 




Figure 5.8: Immunostaining of β- and γ-actin isoforms in shRhoA and shControl NRCF 
Detection of actin isoforms β- (green) and γ-actin (red) by immunofluorescence staining of 
shControl and shRhoA NRCF. In addition, the cell nuclei were stained with DAPI (blue) 
(320x). 
 
As shown above by immunoblot analysis the NRCF express besides β- and γ-actin also α-
sm-actin, which was found to be reduced in shRhoA NRCF. Detection of α-sm-actin by 
immunofluorescence showed that this actin isoform can be detected in the whole cell but with 
a higher accumulation in the cell middle. This was true for shControl as well as shRhoA 
NRCF (Figure 5.9).  
 
Figure 5.9: Immunostaining of α-sm-actin in shRhoA and shControl NRCF Detection of 
α-sm-actin (green) by immunofluorescence staining and total actin by TRITC-phalloidin (red) 
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of shControl and shRhoA NRCF. In addition, the cell nuclei were stained with DAPI (blue) 
(320x). 
 
In addition to actin filament proteins, the intermediate filament protein vimentin and the 
microtubule protein α-tubulin were stained by specific antibodies in shRhoA and shControl 
NRCF. As shown in figure 5.10 no obvious changes could be detected in the distribution or 
integrity of both filaments. 
 
Figure 5.10: Immunostaining of vimentin and α-tubulin in shRhoA and shControl 
NRCF Detection of vimentin (upper two panels, green) and α-tubulin (lower two panels, 
green) by immunofluorescence staining and total actin by TRITC-phalloidin (red) of shControl 




In contrast to α-tubulin, the posttranslational modified acetylated tubulin was found 
significantly upregulated in immunoblot analysis. Interestingly, immunofluorescence staining 
of acetylated tubulin in shControl and shRhoA NRCF showed a condensed area of 
acetylated microtubules in the perinuclear region. In a co-staining of acetylated tubulin with 
wheat germ agglutinin (WGA) the condensed area was found to be in the area of the Golgi 
apparatus (Figure 5.11).  
 
 
Figure 5.11: Co-staining of acetylated tubulin and the Golgi apparatus in shRhoA and 
shControl NRCF Detection of acetylated tubulin (red) by immunofluorescence staining and 
of the Golgi apparatus by Alexa Fluor 488-labeled wheat germ agglutinin (green) in shControl 
and shRhoA NRCF. In addition, the cell nuclei were stained with DAPI (blue) (400x).  
 
 5.1.6 The Golgi apparatus morphology is changed in lentiviral-infected NRCF 
 
The condensed area of actylated tubulin below the Golgi apparatus led to the hypothesis that 
this tubulin modification is important for Golgi morphology and that Golgi size and density 
could be influenced by a change in acetylation level and thus by RhoA. 
WGA-stainings of Golgi membranes in shControl and shRhoA NRCF showed a clear change 
in Golgi morphology. The morphometric analysis of Golgi size and density revealed that the 
area of Golgi membranes is not larger but significantly more condensed in shRhoA 




Figure 5.12: Evaluation of the Golgi apparatus size and density in shRhoA and 
shControl NRCF Representative fluorescence stainings of the Golgi apparatus by Alexa 
Fluor 488-labeled WGA (640x) (left). Morphometric analysis of Golgi size (middle) and 
density (right) of shControl and shRhoA NRCF (means ± SEM; n = 3, at least 10 cells per 
condition and experiment were analyzed, *p < 0.05). 
 
5.1.7 Tubastatin A rescues the Golgi apparatus in RhoA knockdown cells 
 
Upon treatment with the HDAC6 inhibitor tubastatin A (TubA), which induces an increase in 
acetylation of tubulin (see figure 5.13), it was found that this hyperacetylation stabilizes the 
Golgi membrane network in shRhoA NRCF. The increased density of the Golgi stacks in 
shRhoA NRCF could be reversed by application of TubA as assed by WGA-staining and 
morphometric analyses. Interestingly, TubA had no significant impact on the structure of the 
Golgi apparatus in shControl NRCF (Figure 5.13). 
 
Figure 5.13: Analysis of the Golgi apparatus structure in shRhoA and shControl NRCF 
treated with TubA Morphometric analysis of Golgi density (left) and size (right) of shControl 
and shRhoA NRCF in the absence and presence of 5 µg/mL TubA (means ± SEM; n = 3, at 
least 10 cells per condition and experiment were analyzed, *p < 0.05). 
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5.1.8 Latrunculin A disrupts f-actin but does not change cytoskeletal protein 
expression in wild type NRCF 
 
To investigate, whether the increase in tubulin acetylation is regulated by RhoA or a 
compensatory mechanism due to the loss of actin stress fibers or other actin structures, wild 
type NRCF were treated with the g-actin binding agent latrunculin A (LatA) to cause f-actin 
depolymerization. The concentration of LatA used created a mild phenotype similar to the 
RhoA knockdown.  
Staining of total actin with TRITC-phalloidin showed a destabilized cytoskeleton with 
fragmented f-actin in LatA-treated cells after 4 h. At this early time point the collapse of the 
Golgi membrane network was detectable by WGA staining already (Figure 5.14 A). However, 
in immunoblot analyses neither a change in β- and α-sm-actin nor in total and acetylated 
tubulin was found even after treatment with 8.5 µM LatA for 24 h (Figure 5.14 B).  
 
Figure 5.14: Impact of LatA on the cytoskeleton and the Golgi apparatus in NRCF A) 
Representative stainings of total actin by TRITC-phalloidin and of the Golgi apparatus by 
Alexa Fluor 488-WGA in untreated cells and cells treated with 8.5 µM LatA for 4 h are 
presented (200x) (left). Representative magnified images of the Golgi for both conditions are 
shown in addition (640x)(right) B) Quantitative analysis by immunoblot of β-actin expression 
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in equal amounts of total cell lysates (left), α-sm-actin expression (second from left) and 
tubulin expression (second from right) normalized to β-actin as well as expression of 
acetylated tubulin normalized to total tubulin (right) are shown. The relative changes in cells 
treated with 8.5 µM LatA for 24 h to untreated cells are given (means ± SEM, n = 7). 
 
5.1.9 Inhibition of ROCK affects the cell morphology but not the Golgi structure or 
cytoskeletal protein expression in wild type NRCF 
 
To identify the downstream effectors that mediate the impact of the RhoA knockdown on cell 
morphology, Golgi structure and protein expression, wild type NRCF were treated with 
ROCK and HDAC6 inhibitors. For ROCK inhibition 10 µM fasudil and 300 nM of the more 
specific H1152P, for HDAC6 inhibition 5 µg/mL TubA were used. 
Fasudil- and H1152P-treated cells showed an increase in cell area by 100% and in perimeter 
by 25% compared to untreated control cells. In addition, stainings of the actin cytoskeleton 
revealed a loss of stress fibers, a disruption of actin structures and an epithelial-like 
phenotype very similar to the one found in shRhoA NRCF. The inhibition of HDAC6 by TubA 
on the other hand had no effect on cell morphology. The cells still showed prominent stress 
fibers and a myofibroblast-typical shape without any differences in area and perimeter 




Figure 5.15: Morphometric analysis of fasudil-, H1152P- and TubA-treated wild type 
NRCF A) Representative actin stainings with TRITC-phalloidin of untreated (control) (left) 
and fasudil- (10µM) (middle) or TubA- (5 µg/mL) (right) treated cells (400x). B) Quantification 
of cell area (left) and perimeter (right) of untreated or fasudil- (10 µM), H1152P- (300 nM) 
and TubA- (5 µg/mL) treated cells was performed (means ± SEM; n = 3, at least 50 cells per 
condition and experiment were analyzed, *p < 0.05).  
 
Morphological analysis of WGA-positive membranes showed, that neither the treatment with 
fasudil nor with TubA caused an increase in density or in size of the Golgi in wild type NRCF 
(Figure 5.16).  
 
Figure 5.16: Morphometric analysis of the Golgi apparatus of wild type NRCF after 
fasudil and TubA treatment The morphometric analysis of Golgi size (left) and density 
(right) of untreated (control), fasudil- (10 µM) and TubA- (5 µg/mL) treated cells is shown 
(means ± SEM; n = 3, at least 10 cells per condition and experiment were analyzed). 
 
In addition, the treatment of wild type NRCF with fasudil or TubA for 24 h as well as for 4 
days did not influence the expression of α-sm-actin. Also, a change in acetylated tubulin in 
fasudil-treated cells could not be detected. The increase of acetylated tubulin by 4-fold in 




Figure 5.17: Analysis of protein expression in fasudil- and TubA-treated wild type 
NRCF The quantification of α-sm-actin expression normalized to β-actin (left) and the 
acetylated tubulin expression normalized to total tubulin (right) in fasudil- (10 µM) and TubA- 
(5 µg/mL) treated cells relative to untreated (control) cells is shown (means ± SEM, n = 7).  
 
5.2 Influence of RhoA on the morphology of focal adhesion sites and on the 
adhesion velocity of NRCF 
 
The observed changes in cell morphology and cytoskeletal arrangement in shRhoA NRCF 
led to the hypothesis that this could have an impact on the adhesion velocity and the 
arrangement of focal adhesion sites in these cells.  
 
5.2.1 The RhoA knockdown leads to a random distribution and reduced length of 
focal adhesion sites 
 
Vinculin, a protein associated with focal adhesion sites, was found to be unchanged in 
immunoblot analyses. However, immunofluorescence staining revealed a more random 
distribution of vinculin throughout shRhoA compared to shControl NRCF (Figure 5.18 A). The 
deviation from the cell axis and the length of focal adhesion sites was quantified in both cell 
types. In shRhoA NRCF focal adhesion sites were significantly shorter and had in average a 




Figure 5.18: Analysis of focal adhesion site size and distribution in shRhoA and 
shControl NRCF A) Representative immunoblots of vinculin and β-actin in shControl and 
shRhoA NRCF lysates are shown (left). Detection of vinculin (green) by immunofluorescence 
staining and total actin by TRITC-phalloidin (red) of shControl and shRhoA NRCF are 
presented. In addition, the cell nuclei were stained with DAPI (blue) (320x). B) Quantification 
of focal adhesion site length assessed by vinculin immunofluorescence staining in shRhoA 
NRCF relative to shControl NRCF is shown (means ± SEM; n = 3, at least 5 cells per 
condition and experiment were analyzed, *p < 0.05). 
 
5.2.2 The knockdown of RhoA increases the adhesion velocity 
 
The knockdown of RhoA had also an impact on adhesion velocity. Both on a cell culture 
surface and on a collagen-coated surface more shRhoA NRCF were attached after 30 min 
compared to shControl NRCF (Figure 5.19). The overall difference between both cell types 




Figure 5.19: Analysis of the adhesion velocity of shRhoA and shControl NRCF 
Quantification of the number of adherent cells on cell culture-treated (left) and collagen-
coated surfaces (right) is shown. The number of adherent shRhoA and shControl NRCF at 
each time point in percent is given (means ± SEM, n = 4, *p < 0.05). 
 
5.3 Influence of RhoA on the migration capacity of NRCF 
 
Since shRhoA NRCF showed a random distribution of focal adhesion sites and a disruption 
of the cytoskeleton, it was investigated whether this could lead to impaired migratory 
performance. The same experiment was performed with fasudil- and TubA-treated wild type 
NRCF for comparison. 
 
5.3.1 The knockdown of RhoA impairs the migration performance on a plane surface 
 
The migration on a surface was assessed by tracking shControl and shRhoA as well as 
inhibitor-treated NRCF over 24 hours after visualizing the actin cytoskeleton with a GFP-
tagged f-actin-binding polypeptide (LifeAct). ShRhoA NRCF showed a reduction in the 
migration velocity by 60% and a decreased absolute migration distance by 50% compared to 
shControl NRCF when tracked over a time course of 24 h (Figure 5.20 A). Similar findings 
were obtained by treating wild type NRCF with fasudil, which decreased the total distance by 
60% and the migration velocity by 75%. TubA, on the other hand, reduced absolute distance 




Figure 5.20: Analysis of the migration on a plane surface of shRhoA, shControl and 
inhibitor-treated NRCF A) Quantification of the absolute distance migrated (left) and 
average migration velocity (right) of shControl and shRhoA NRCF on a cell culture surface 
over a time course of 24 h is shown (means ± SEM; n = 3, at least 14 cells per condition and 
experiment were analyzed, *p < 0.05). B) Quantification of the absolute distance migrated 
(left) and average migration velocity (right) of untreated (control), fasudil- (10 µM) and TubA- 
(5 µg/mL) treated cells on a cell culture surface over a time course of 24 h is shown (means 
± SEM; n = 3, at least 14 cells per condition and experiment were analyzed, *p < 0.05). 
 
5.3.2 The invasive migration capacity is improved after RhoA knockdown but not 
after inhibitor treatment 
 
The capacity of invasive migration through pores of lentiviral-infected and inhibitor-treated 
NRCF was assessed by seeding the cells on a porous membrane. The number of cells 
located inside the pores after a time course of 24 h was evaluated. All experiments were 
performed with and without a serum stimulus.  
Under serum-reduced and high serum conditions shRhoA NRCF showed an improved 
invasive migration performance compared to shControl NRCF. In fact, the migration rate of 
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shRhoA NRCF without serum stimulation was already as high as the rate of shControl NRCF 
under high serum conditions (Figure 5.21 A).  
The same experiment was performed with wild type NRCF and the indicated inhibitors. Cells 
treated with fasudil showed a 50% decrease in invasive migration in both reduced and high 
serum conditions compared to untreated cells. In addition, TubA decreased the number of 
cells inside the pores by 30% in serum-reduced conditions compared to control, however, 
this effect was diminished by a high serum stimulus (Figure 5.21 B).  
 
Figure 5.21: Analysis of the invasive migration of shRhoA, shControl and inhibitor-
treated NRCF A) Quantitative analysis of shControl and shRhoA NRCF inside a porous 
membrane (pore size: 8 µm) assessed by Hoechst staining in low serum (1%) and high 
serum (10%) conditions is presented. The absolute number of cells is given (means ± SEM, 
n = 5, *p < 0.05). B) Quantitative analysis of untreated (control), fasudil- (10 µM) and TubA- 
(5 µg/mL) treated cells inside a porous membrane (pore size: 8 µm) assessed by Hoechst 
staining in low serum (1%) and high serum (10%) conditions is shown. The absolute number 
of cells is given (means ± SEM, n = 5, *p < 0.05). 
 
5.4 Influence of RhoA on the proliferation of NRCF 
 
The ability to proliferate is one of the typical myofibroblast characteristics that discriminates 
them from the quiescent fibroblasts. As the dynamics of the actin cytoskeleton and of 
microtubules are both essential for the process of cell division, it was investigated if the 
knockdown of RhoA as well as the inhibition of downstream effectors had an impact on the 
doubling time of NRCF.  
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5.4.1 The knockdown of RhoA increases the doubling time of NRCF as does HDAC6 
inhibition 
 
The doubling time of the lentiviral-infected or inhibitor-treated cells was evaluated by a 
proliferation-DAPI-assay with a serum stimulus over a time course of 4 days. 
It was found that shRhoA NRCF had an increase in doubling time by 36% compared to 
shControl NRCF (Figure 5.22 A). Next, the number of apoptotic and necrotic cell in the 
cultures was evaluated to exclude an increase in cell death. In a co-staining of Annexin-V-
FLUOS and propidium iodide no elevated levels and no difference between shRhoA and 
shControl NRCF were observed (Figure 5.22 B).  
 
 
Figure 5.22: Analysis of proliferation and cell death of sRhoA and shControl NRCF A) 
Shown is the quantitative analysis of the proliferation-DAPI assay of shControl and shRhoA 
NRCF with a serum stimulus (10% FCS) over a time course of 4 days. The absolute cell 
numbers at the different time points were assessed by DAPI staining. Given is the relative 
increase in cell number compared to day 0 (means ± SEM, n = 5, *p < 0.05). B) 
Quantification of apoptotic (left) and necrotic (right) shControl and shRhoA NRCF by 
Annexin-V-FLUOS and propidium iodide stainings is shown. The number of cells in percent 
is given (means ± SEM, n = 3) 
 
The found changes in cell doubling time were compared to wild type NRCF treated with 
fasudil, H1152P and TubA. First, ROCK inhibitors did not significantly change the doubling 
time of the cells compared to untreated cells. Second, the treatment of TubA was found to 




Figure 5.23: Analysis of the proliferation of NRCF treated with ROCK inhibitors and 
TubA Shown is the quantitative analysis of the proliferation-DAPI assay of untreated 
(control), fasudil- (10µM), H1152P- (300nM) and TubA- (5µg/mL) treated NRCF with a serum 
stimulus (10% FCS) over a time course of 4 days. The absolute cell numbers at the different 
time points were assessed by DAPI staining. Given is the relative increase in cell number 
compared to day 0 (means ± SEM, n = 3, *p < 0.05). 
 
5.4.2 ROCK and HDAC6 inhibitors affect the actin cytoskeleton and the proliferation 
of normal adult human ventricular cardiac fibroblasts 
 
Preliminary data about the effect of ROCK and HDAC6 inhibitors on normal adult human 
ventricular cardiac fibroblasts (NHCF-V) was obtained from actin stainings by TRITC-
phalloidin and by a proliferation-DAPI-assay. A change in morphology to an epithelial-like 
phenotype after 24 hours of fasudil treatment was also observed in NHCF-V, while TubA had 
no effect on cell morphology (Figure 5.24 A). The proliferation-DAPI-assay was conducted 
with a serum stimulus over a time course of 4 days and the absolute cell number was 
determined at day 3 and 4. At both time points evaluated, TubA-treated NHCF-V showed a 
50% lower absolute cell number, while with both ROCK inhibitors no change was observed 




Figure 5.24: Analysis of the actin cytoskeleton and the proliferation after treatment 
with ROCK inhibitors and TubA in NHCF-V A) Representative actin stainings with TRITC-
phalloidin of untreated (control) (left), fasudil- (10µM) (middle) and TubA- (5 µg/mL) (right) 
treated NHCF-V is shown (320x). B) Shown is the quantitative analysis of a proliferation-
DAPI assays of untreated (control), fasudil- (10µM), H1152P- (300nM) and TubA- (5µg/mL) 
treated NHCF-V with a serum stimulus (10% FCS) over a time course of 4 days. The 
absolute cell numbers at the different time points were assessed by DAPI staining (means ± 
SEM, n = 1, measured in 6 replicates). 
 
5.5 Influence of RhoA on the regulation of CTGF in NRCF 
 
Due to the fact that RhoA has been shown to be involved in the secretion of matrix 
compounds and bioactive factors, it was hypothesized that the RhoA knockdown has also an 
impact on the secretion of the connective tissue growth factor (CTGF). CTGF is an 
intercellular signaling protein that was found to be secreted by cardiac fibroblasts as well as 






5.5.1 CTGF co-localizes with the Golgi apparatus and acetylated tubulin 
 
Immunofluorescence stainings for CTGF and acetylated tubulin as well as WGA stainings of 
the Golgi apparatus in shControl and shRhoA NRCF were performed. The staining revealed 
a co-localization of CTGF with the Golgi and in parts with the acetylated tubulin (Figure 5.25). 
 
Figure 5.25: Co-stainings of acetylated tubulin, the Golgi apparatus and CTGF in 
shControl and shRhoA NRCF Detection of acetylated tubulin (red) and CTGF (yellow) by 
immunofluorescence staining as well as staining of the Golgi apparatus by Alexa Fluor 488-
labeled WGA (green) in shControl and shRhoA NRCF. In addition, the cell nuclei were 
stained with DAPI (blue) (320x).  
 
5.5.2 The knockdown of RhoA affects the expression and secretion of CTGF under 
low-serum conditions in NRCF 
 
The co-localization of CTGF and the Golgi apparatus with the condensed area of acetylated 
tubulin led to the hypothesis that the knockdown of RhoA, which influenced the Golgi 
morphology and tubulin acetylation, could have an impact on the regulation of CTGF. 
ShControl and shRhoA NRCF were cultured under serum-reduced (1%) or high serum (10%) 
conditions. The intracellular CTGF was then assessed by immunoblot analyses of the whole 
cell lysates, extracellular CTGF by the analysis of the culture medium, which revealed a 
decrease in intracellular CTGF by 30% and in extracellular CTGF by 40% in serum-reduced 




Figure 5.26: Analysis of CTGF expression and secretion in shRhoA and shControl 
NRCF under serum-reduced conditions A) Representative immunoblots of extracellular 
(extr.) CTGF, intracellular (intr.) CTGF and β-actin from shControl and shRhoA NRCF 
cultured under serum-reduced conditions (1% FCS) are shown (left). B) Quantification of 
intracellular (middle) and extracellular (right) CTGF normalized to β-actin is shown. The 
relative changes in shRhoA versus shControl are given (means ± SEM, n = 7, *p < 0.05). 
 
In contrast to serum-reduced conditions, no change in the amount of the intracellular CTGF 
in shRhoA compared to shControl NRCF could be detected under high-serum conditions. 
Interestingly, the amount of extracellular CTGF was found to be increased by 30% in shRhoA 
NRCF (Figure 5.27). 
 
Figure 5.27: Analysis of CTGF expression and secretion in shRhoA and shControl 
NRCF under high serum conditions A) Representative immunoblots of extracellular (extr.) 
CTGF, intracellular (intr.) CTGF and β-actin from shControl and shRhoA NRCF cultured 
under high serum conditions (10% FCS) are shown (left). B) Quantification of intracellular 
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(middle) and extracellular (right) CTGF normalized to β-actin is shown. The relative changes 
in shRhoA versus shControl are given (means ± SEM, n = 6, *p < 0.05). 
 
5.5.3 Hyperacetylated tubulin increases extracellular CTGF solely in RhoA 
knockdown NRCF 
 
Next the impact of acetylated tubulin on extracellular and intracellular CTGF was 
investigated. It was hypothesized that hyperacetylation of tubulin induced by TubA treatment 
can influence intracellular and extracellular CTGF amounts in lentiviral-infected cells.  
To investigate this, shControl and shRhoA NRCF were treated with TubA for 24 h under 
high-serum conditions. First, it was found that TubA had no impact on the intracellular level 
of CTGF in shRhoA or shControl and on the extracellular CTGF in shControl NRCF. Second, 
the hyperacetylation of tubulin induced by TubA increased the extracellular CTGF in shRhoA 
NRCF up to 70% compared to shControl (Figure 5.28). 
 
Figure 5.28: Analysis of CTGF expression and secretion in shRhoA and shControl 
NRCF under high serum conditions and additional TubA treatment A) Representative 
immunoblots of extracellular (extr.) CTGF, intracellular (intr.) CTGF and β-actin from 
shControl and shRhoA NRCF cultured under high serum conditions (10% FCS) and treated 
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with 5 µg/mL Tub A as indicated are shown. B) Quantification of intracellular (left) and 
extracellular (right) CTGF normalized to β-actin is shown. The relative changes in shRhoA 
versus shControl are given (means ± SEM, n = 5, *p < 0.05). 
 
5.6 Influence of RhoA on the contractile performance of engineered heart muscles 
 
The analysis of engineered heart muscles (EHM) complemented with lentiviral-infected 
fibroblasts provided an insight into the function of these cells within a more “native” 
environment. 
5.6.1 shRhoA NRCF complemented EHM develop less contractile force 
 
Evaluation of the contractile parameters revealed that EHM complemented with additional 
shRhoA NRCF did not show a change in resting force (RF) compared to ones complemented 
with shControl NRCF. Interestingly, upon calcium stimulation shRhoA NRCF complemented 
EHM developed a force of contraction 40% lower than EHMs complemented with shControl 
NRCF at high calcium concentrations (Figure 5.29). 
 
Figure 5.29: Contraction experiments of EHM complemented with shControl and 
shRhoA NRCF Contraction experiments of engineered heart muscle (EHM) complemented 
with shControl and shRhoA NRCF. Evaluation of the resting force (RF, left) and the force of 
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contraction (FOC) under increasing calcium concentrations (right) is shown (means ± SEM, 
n = 3, at least 2-4 EHMs per experiment and condition were analyzed, *p < 0.05). 
 
5.6.2 EHM complemented with RhoA knockdown cells express less α-sm-actin and 
calsequestrin 
 
After contraction experiments the final protein composition of the EHMs was assessed by 
immunoblot analyses. It was found that RhoA, β-actin, H3, tubulin and CTGF were 
unchanged in shRhoA NRCF complemented EHM compared to those containing shControl 
NRCF. An increasing trend in acetylated tubulin could be observed, however, was not found 
to be significant. Interestingly, expression levels of α-sm-actin and the cardiomyocyte marker 
calsequestrin were significantly decreased in shRhoA complemented EHM compared to 
shControl (Figure 5.30). 
 
Figure 5.30: Analysis of protein composition of EHM complemented with shControl 
and shRhoA NRCF Representative immunoblots of cytoskeletal proteins, calsequestrin, 
intracellular CTGF and histone H3 in cell lysates obtained from shControl and shRhoA NRCF 
complemented EHM are shown (left). Quantitative analysis of EHM protein composition 
normalized to vimentin is shown. The relative change of shRhoA NRCF complemented 
versus shControl NRCF complemented EHM is given (means ± SEM, n = 3, at least 2-4 






Generation of a BiFC-based biosensor plasmid to visualize RhoA activity in living cells 
Based on the cloning strategy described in the chapter 3, a plasmid encoding for a fusion 
protein was generated containing the sequences for the N-terminus of venus-YFP, for RhoA 
with the Rho-binding domain of rhotekin (RBD) and for the C-terminus of venus-YFP. The 
plasmid was then transfected in HEK293A cells and the expression of the fusion protein was 
investigated by immunoblot analyses. Both the antibodies against RhoA and against YFP 
detected the sensor protein with an approx. molecular weight of 66 kDa (Figure 5.31). 
 
Figure 5.31: Analysis of the BiFC sensor protein expression in HEK293A cells by 
immunoblot Immunoblot analysis of RhoA and YFP in whole cell lysates obtained from 
HEK293A cells transfected with pcDNA3.1(+)/Zeo (pcDNA), the BiFC sensor plasmid (BiFC), 
or two control plasmids coding for YFP and RhoA-2xMyc. 
 
The cells transfected with the sensor plasmid showed a fluorescence signal in the YFP 
channel and a mild rounded phenotype comparable with the cells transfected with wild type 





Figure 5.32: Analysis of the BiFC sensor expression in HEK293A cells by fluorescence 
microscopy Representative bright field and fluorescence images of HEK293A cells 
transfected with pcDNA3.1(+)/Zeo ((pcDNA), the BiFC sensor plasmid (BiFC), or two control 





During pathological remodeling the heart undergoes changes in function, shape and cellular 
composition. The transition of quiescent fibroblasts into myofibroblasts contributes to these 
changes by an increased ECM deposition creating interstitial and perivascular fibrosis or a 
scar tissue in case of myocardial infarction. The underlying signaling events inducing the 
transition of cardiac fibroblasts to myofibroblasts or controlling the typical myofibroblast 
characteristics like migration, proliferation or secretion are still not completely understood. 
Based on the well-known fact that in these processes the control of the actin cytoskeleton 
and microtubules is essential, a role of the monomeric GTPase RhoA, which is a prominent 
regulator of the cytoskeleton, was postulated. So far there is no systematic study on the 
function of RhoA in cardiac fibroblasts. Therefore, in this thesis a lentiviral-induced 
knockdown and small-molecule inhibitors were used to assess the impact of a reduction in 
RhoA expression as well as the inhibition of RhoA downstream effectors, respectively, on the 
cardiac myofibroblast.  
 
6.1 RhoA influences the cytoskeleton, the cell morphology and the adhesion of 
NRCF 
 
The knockdown of RhoA in NRCF by a small hairpin construct was shown to reduce the 
expression of RhoA on mRNA and protein level, while the two homolog family members 
RhoB and RhoC were not affected. Thus the knockdown and its outcome were considered to 
be specific.  
In brief, the knockdown of RhoA resulted in a disruption of higher order actin structures, in an 
increase in the cell surface of adherent cell and a faster adhesion independent of the 
substratum. All this aspects are in line with the main postulated function of RhoA – its 
regulation of actin filaments. Although many of these features have not been assigned before 
to RhoA in cardiac fibroblasts, there is numerous literature demonstrating similar effects in 
other cell types.  
For example, in this work the downregulation of RhoA led to a loss of geodesic actin dome 
structures in NRCF. These structures are rather rare and could not be observed in many 
other cells, but Malek et al. investigated in 2007 geodesic actin that forms from stress fibers 
in the perinuclear region of endothelial cells under hypertonic conditions. They could show 
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that these complex actin structures are dependent on RhoA and ROCK as the use of C3T 
and the ROCK inhibitor Y-27632 completely suppressed their formation [152]. So far the 
function of these geodesic dome structures is not clear. Entcheva et al. postulated in 2009, 
that in NRCF geodesic actin is a precursor of stress fibers and gets transformed into those 
over time Furthermore, the authors showed that the nuclei in geodesic dome cells are more 
round-shaped and smaller, which is probably due to the lack of the intracellular tension as 
compared to stress fiber containing cells [153]. These findings might explain why in this work 
the shRhoA NRCF showed neither clear geodesic domes nor extensive stress fibers, but 
also why the knockdown of RhoA resulted in an increase in cell size. This is very likely due to 
the loss of the actin-dependent intracellular tension in case of stress fibers and the loss of 
the stability providing domes which are at least known from architecture to be highly resistant 
against tension and compression [154]. Moreover, the loss of these structures may also 
explain why the shRhoA NRCF display an increased adhesion velocity. Adhesion is a 
process which relays on the concerted activation of Rac1 and RhoA. Especially, in the early 
phase RhoA activation is counterproductive and inhibited by RhoGAPs like p190RhoGAP. 
Fibroblasts overexpressing a dominant negative variant of this GAP have been at least 
shown to display augmented cell spreading [155].  
Mechanistically, the observed phenotype in shRhoA NRCF could be at least explained in 
parts. On the one hand, with respect to the actin cytoskeleton and the increased cell area 
similar results were obtained with the two ROCK inhibitors fasudil and H1152P indicating that 
the observed changes are ROCK-mediated. ROCK was already connected in 2007 by 
Harvey et al. to a morphological change in lung fibroblasts. The group demonstrated an 
increase in cell area after H1152P treatment and with a simultaneous reduction in stress fiber 
formation [156]. On the other hand, shRhoA NRCF displayed a reduction in the expression of 
the myofibroblast marker α-sm-actin [157-159] which is likely regulated by the MAL-induced 
activation of the SRF [76]. In this context, it has been shown that the integration of α-sm-
actin in stress fibers leads to the formation of strong contractile fibrils and enables 
myofibroblasts to efficiently contract the ECM [93, 160] [161]. This process is especially of 
relevance after a myocardial infarction as a reduction in α-sm-actin levels in fibroblasts within 
the scarring area leads to poor wound closure and even to ventricular wall rupture [162]. 
Besides this, it is completely unclear what the role of the RhoA-dependent changes in the 
actin structures, in cell adhesion and spreading are within the native tissue. It can be 
assumed that in a heart, fibroblasts are neither of the pure stress fiber nor of the pure 
geodesic dome phenotype as the rigidity of the substratum, the tensile forces, the 
composition of the ECM and the paracrine environment is completely different than in a cell 
culture dish. However, the ability to react to changes in these parameters, as it occurs in 
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heart disease, very likely requires a response on the level of the actin cytoskeleton and thus 
requires RhoA. One of the processes which occur in heart disease and rely on such a 
response is cell migration. 
 
6.2 RhoA influences NRCF migration  
 
In this work, the knockdown of RhoA in NRCF led to decrease in cell migration on a plane 
surface which is easily explained by the disruption of the actin cytoskeleton and by the loss 
of cell polarity as demonstrated by vinculin staining. Similar data have been presented by 
different groups in various cell types and in accordance to the data presented in this thesis 
an involvement of ROCK has been discussed [163, 164] [165] [166].  
More interestingly and probably more relevant in a tissue, the knockdown of RhoA in NRCF 
was found to improve the invasive migration. In pathological cardiac remodeling the invasive 
migration by myofibroblasts through the ECM is essential for the development of interstitial 
fibrosis and scar tissue and is enabled by secreting MMPs to degrade the scaffold in their 
path [80-83]. With the findings described in this thesis, RhoA can thus be connected to the 
invasive migratory performance of myofibroblasts. Mechanistically, it is not clear how RhoA 
regulates the invasive migration, especially, as an inhibition of ROCK led to the opposite 
effect, namely a reduction in migration. This discrepancy cannot be explained so far and has 
to be further investigated in the future. 
 
6.3 RhoA controls myofibroblast proliferation by changes in tubulin stability 
 
The ability to proliferate distinguishes the senescent fibroblast from its activated counterpart. 
The actin and tubulin cytoskeleton are known to be equally involved in the process of 
cytokinesis by forming the contractile cortical ring and separating the chromosomes. In this 
thesis, the proliferation rate was found to be decreased in shRhoA NRCF which could be 
shown to be dependent on the activity of HDAC6 ergo on an increase in tubulin acetylation. 
A direct link between RhoA and human atrial fibroblast proliferation was described by Porter 
et al. in 2004 where the reduction of active RhoA similarly reduced the proliferation rate [93]. 
The fact that HDAC6 inhibition and therefore stabile acetylated tubulin negatively regulate 
the proliferative capacity of cells was described before by Azuma et al. described in a 
mammary cancer cell line [167] and by Aguilar et al. in mouse fibroblasts [168]. The effect of 
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HDAC6 on proliferation in myofibroblasts has not been described so far. Nevertheless, the 
ability of myofibroblasts to proliferate is essential for pathological remodeling processes. In 
acute events, other myofibroblasts precursor from bone marrow like fibrocytes or endothelial 
cells undergoing EMT are recruited, however, the number of cells has to be increased 
similarly by proliferation of resident fibroblasts [103, 169].  
Mechanistically, the link between RhoA and HDAC6 is not clear in cardiac fibroblasts. By this 
thesis at least the involvement of ROCK could be excluded as postulated before by Schofield 
et al. which demonstrated in HEK293 cells that ROCK can influence HDAC6 activity via the 
tubulin polymerization promoting protein 1 (TPPP1) [170]. Alternatively, mDia2 might be the 
mediator as shown before in osteoclasts [72]. Further studies have to clarify this issue to 
deepen the understanding of the mitogenic role of RhoA and HDAC6 in cardiac fibroblasts. 
Especially, as HDAC6 has been shown to plays a role in atrial fibrillation which is 
characterized by an activation and proliferation of atrial fibroblasts [93, 171, 172]. 
 
6.6 RhoA controls intracellular and extracellular CTGF and a change in Golgi 
morphology in NRCF 
 
 A quiescent fibroblast as found in the healthy cardiac tissue secretes ECM components just 
to maintain a slow constant matrix turnover. However, upon activation by a profibrotic 
stimulus or mechanic force myofibroblasts secrete a wide variety of cytokines and growth 
factors amongst them the connective tissue growth factor (CTGF). The downregulation of 
RhoA led in this thesis in serum-reduced conditions to a significant decrease in expression 
and secretion of CTGF. It was already shown before by Mun et al. and Laval et al. that RhoA 
[80] and ROCK inhibition [53] impaired CTGF expression in keloid fibroblasts and NRCF, 
respectively. In addition, the expression of CTGF was recently connected to the binding of 
the SRF [173]. To date, the RhoA mediated secretion of CTGF was not investigated in NRCF 
but was shown before to be processed through the Golgi in dermal fibroblasts [174]. Upon 
investigation, the Golgi membrane structure was found more condensed in shRhoA NRCF. 
The same effect on Golgi morphology was observed by Camera et al in neuronal cells after 
treatments with C3T [175] and by Lázaro-Diéguez et al. after treatment of vero cells with 
LatA [176] and therefore can be connected to RhoA activity and f-actin integrity. The 
downstream effector that mediated the condensation of the Golgi in shRhoA NRCF was not 
identified in this thesis but it was published before that the formin mDia1, which can be 
activated by RhoA, has a possible role in Golgi morphology [177]. The condensation of the 
Golgi structure was described by Ng et al. to induce a decrease, while a dispersion of the 
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membranes leads to an increase in secretory performance [178]. This could explain why the 
treatment with TubA that rescued the Golgi structure in shRhoA NRCF led to an improved 
secretion of CTGF. Whether the condensation of the Golgi or the knockdown of RhoA itself 
led to the decrease in intracellular and extracellular CTGF in shRhoA NRCF is not clear and 
needs further investigation. The role of CTGF in the heart is to date still obscure. It is 
considered a pro-fibrotic factor, while there is also growing evidence of its cardiomyocyte-
protective function [179-182] in hypertrophic growth. 
 
6.7 EHM complemented with shRhoA NRCF develop less contractile force and 
show signs of cardiomyocyte loss 
 
In this these EHM were used a 3D tissue model to investigate the effect of a RhoA 
knockdown in NRCF on contractile force during calcium stimulation. It was found that 
shRhoA NRCF complemented EHMs showed no difference in resting tension, however, the 
contractile force with increasing stimulus was significantly reduced compared to shControl 
NRCF complemented EHM. The analyses of protein content revealed a significant reduction 
in cardiomyocyte marker calsequestrin as well as the myofibroblast marker α-sm-actin. The 
evaluation of contractile force development in EHMs complemented with RhoA knockdown 
fibroblasts has not been described before. Nevertheless, a comparable study was published 
by Mühlhäuser et al. in 2006. The group treated EHM with atorvastatin and performed 
contraction experiments using increasing concentrations of isoproterenol. It was found that 
atorvastatin had no effect on resting tension but decreased contractile force concentration-
dependent up to 50% [183]. The reduction of the calsequestrin possibly illustrates a loss of 
cardiomyocytes in shRhoA NRCF complemented EHM which could explain the observed 
reduction in contractile force. Interestingly, a decreasing trend of the expression of CTGF 
was observed as well in shRhoA EMHs which gives a possible explanation for the loss of 
contractile cells. It was already described that CTGF has a pro-hypertrophic as well as an 
anti-apoptotic effect on cardiomyocytes and thus allow an adaptive growth response of the 
heart and therefore exerts a protective effect after increased workload [182, 184]. But also 
the changed regulation and secretion of other beneficial factors from cardiac fibroblasts is 
thinkable [185] Secretome analyses of cardiac fibroblasts with a regulation in RhoA 
expression will help in the future to further broaden the understanding of RhoA in the 







The data obtained in this thesis clearly argues for a major role of RhoA not only in 
myofibroblast characteristics but also in the maintenance of cell integrity and Golgi 
morphology. For the prominent downstream effectors of RhoA, investigated distinct functions 
and contributions to the myofibroblastic phenotype were identified. RhoA was therefore 
connected to the activation of cardiac fibroblasts seen in the induction of pathological 
remodeling, especially in cardiac fibrosis. Although the data collected in this thesis does not 
argue for RhoA as a potential drug target in the future, it increased the knowledge about its 
function in the cardiac fibroblasts and supports the already described beneficial effects of 
ROCK and HDAC6 inhibitors in the outcome of cardiovascular diseases including pulmonary 
arterial hypertension or atrial fibrillation, respectively.  
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